Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with...
Saved in:
| Published in: | Nature reviews. Clinical oncology Vol. 19; no. 1; pp. 37 - 50 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
Nature Publishing Group UK
01.01.2022
Nature Publishing Group |
| Subjects: | |
| ISSN: | 1759-4774, 1759-4782, 1759-4782 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with various forms of advanced-stage cancer; however, the majority of patients receiving these therapies, even in combination, do not derive clinical benefit. Further development of agents targeting additional immune checkpoints, co-stimulatory receptors and/or co-inhibitory receptors that control T cell function is therefore critical. In this Review, we discuss the translational potential and clinical development of agents targeting both co-stimulatory and co-inhibitory T cell receptors. Specifically, we describe their mechanisms of action, and provide an overview of ongoing clinical trials involving novel ICIs including those targeting LAG3, TIM3, TIGIT and BTLA as well as agonists of the co-stimulatory receptors GITR, OX40, 41BB and ICOS. We also discuss several additional approaches, such as harnessing T cell metabolism, in particular via adenosine signalling, inhibition of IDO1, and targeting changes in glucose and fatty acid metabolism. We conclude that further efforts are needed to optimize the timing of combination ICI approaches and, most importantly, to individualize immunotherapy based on both patient-specific and tumour-specific characteristics.
Immune-checkpoint inhibitors have dramatically improved the outcomes in patients with advanced-stage cancers, although the majority of patients will not respond to these agents. Here, the authors describe the potential of targeting emerging immunomodulatory pathways, with a focus on alternative immune checkpoints and tumour metabolism as approaches that might enable further improvements in the outcomes of patients with cancer, either as monotherapies or in combination with existing agents.
Key points
Immune-checkpoint inhibitors (ICIs) have revolutionized cancer therapy, although clinically approved agents are currently restricted to those targeting PD-1/PD-L1 or CTLA4. The addition of therapies targeting a wider range of immune checkpoints will enable improved outcomes.
Among co-inhibitory immune checkpoints, targets include LAG3, TIM3, TIGIT and BTLA, with agents targeting LAG3 currently the most advanced in terms of clinical development.
Antibodies against co-stimulatory targets, such as GITR, OX40, 41BB and ICOS, have considerable potential to complement the currently available ICIs, although optimizing the timing of administration will be important.
Changes in tumour cell and T cell metabolism are a source of additional targets, both of which have highly promising preclinical data available, albeit with only modest success in clinical trials thus far. |
|---|---|
| AbstractList | The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with various forms of advanced-stage cancer; however, the majority of patients receiving these therapies, even in combination, do not derive clinical benefit. Further development of agents targeting additional immune checkpoints, co-stimulatory receptors and/or co-inhibitory receptors that control T cell function is therefore critical. In this Review, we discuss the translational potential and clinical development of agents targeting both co-stimulatory and co-inhibitory T cell receptors. Specifically, we describe their mechanisms of action, and provide an overview of ongoing clinical trials involving novel ICIs including those targeting LAG3, TIM3, TIGIT and BTLA as well as agonists of the co-stimulatory receptors GITR, OX40, 41BB and ICOS. We also discuss several additional approaches, such as harnessing T cell metabolism, in particular via adenosine signalling, inhibition of IDO1, and targeting changes in glucose and fatty acid metabolism. We conclude that further efforts are needed to optimize the timing of combination ICI approaches and, most importantly, to individualize immunotherapy based on both patient-specific and tumour-specific characteristics.Immune-checkpoint inhibitors have dramatically improved the outcomes in patients with advanced-stage cancers, although the majority of patients will not respond to these agents. Here, the authors describe the potential of targeting emerging immunomodulatory pathways, with a focus on alternative immune checkpoints and tumour metabolism as approaches that might enable further improvements in the outcomes of patients with cancer, either as monotherapies or in combination with existing agents. The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with various forms of advanced-stage cancer; however, the majority of patients receiving these therapies, even in combination, do not derive clinical benefit. Further development of agents targeting additional immune checkpoints, co-stimulatory receptors and/or co-inhibitory receptors that control T cell function is therefore critical. In this Review, we discuss the translational potential and clinical development of agents targeting both co-stimulatory and co-inhibitory T cell receptors. Specifically, we describe their mechanisms of action, and provide an overview of ongoing clinical trials involving novel ICIs including those targeting LAG3, TIM3, TIGIT and BTLA as well as agonists of the co-stimulatory receptors GITR, OX40, 41BB and ICOS. We also discuss several additional approaches, such as harnessing T cell metabolism, in particular via adenosine signalling, inhibition of IDO1, and targeting changes in glucose and fatty acid metabolism. We conclude that further efforts are needed to optimize the timing of combination ICI approaches and, most importantly, to individualize immunotherapy based on both patient-specific and tumour-specific characteristics.The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with various forms of advanced-stage cancer; however, the majority of patients receiving these therapies, even in combination, do not derive clinical benefit. Further development of agents targeting additional immune checkpoints, co-stimulatory receptors and/or co-inhibitory receptors that control T cell function is therefore critical. In this Review, we discuss the translational potential and clinical development of agents targeting both co-stimulatory and co-inhibitory T cell receptors. Specifically, we describe their mechanisms of action, and provide an overview of ongoing clinical trials involving novel ICIs including those targeting LAG3, TIM3, TIGIT and BTLA as well as agonists of the co-stimulatory receptors GITR, OX40, 41BB and ICOS. We also discuss several additional approaches, such as harnessing T cell metabolism, in particular via adenosine signalling, inhibition of IDO1, and targeting changes in glucose and fatty acid metabolism. We conclude that further efforts are needed to optimize the timing of combination ICI approaches and, most importantly, to individualize immunotherapy based on both patient-specific and tumour-specific characteristics. The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with various forms of advanced-stage cancer; however, the majority of patients receiving these therapies, even in combination, do not derive clinical benefit. Further development of agents targeting additional immune checkpoints, co-stimulatory receptors and/or co-inhibitory receptors that control T cell function is therefore critical. In this Review, we discuss the translational potential and clinical development of agents targeting both co-stimulatory and co-inhibitory T cell receptors. Specifically, we describe their mechanisms of action, and provide an overview of ongoing clinical trials involving novel ICIs including those targeting LAG3, TIM3, TIGIT and BTLA as well as agonists of the co-stimulatory receptors GITR, OX40, 41BB and ICOS. We also discuss several additional approaches, such as harnessing T cell metabolism, in particular via adenosine signalling, inhibition of IDO1, and targeting changes in glucose and fatty acid metabolism. We conclude that further efforts are needed to optimize the timing of combination ICI approaches and, most importantly, to individualize immunotherapy based on both patient-specific and tumour-specific characteristics. The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the 2018 Nobel Prize for Medicine and Physiology. This groundbreaking new approach has improved the outcomes of patients with various forms of advanced-stage cancer; however, the majority of patients receiving these therapies, even in combination, do not derive clinical benefit. Further development of agents targeting additional immune checkpoints, co-stimulatory receptors and/or co-inhibitory receptors that control T cell function is therefore critical. In this Review, we discuss the translational potential and clinical development of agents targeting both co-stimulatory and co-inhibitory T cell receptors. Specifically, we describe their mechanisms of action, and provide an overview of ongoing clinical trials involving novel ICIs including those targeting LAG3, TIM3, TIGIT and BTLA as well as agonists of the co-stimulatory receptors GITR, OX40, 41BB and ICOS. We also discuss several additional approaches, such as harnessing T cell metabolism, in particular via adenosine signalling, inhibition of IDO1, and targeting changes in glucose and fatty acid metabolism. We conclude that further efforts are needed to optimize the timing of combination ICI approaches and, most importantly, to individualize immunotherapy based on both patient-specific and tumour-specific characteristics. Immune-checkpoint inhibitors have dramatically improved the outcomes in patients with advanced-stage cancers, although the majority of patients will not respond to these agents. Here, the authors describe the potential of targeting emerging immunomodulatory pathways, with a focus on alternative immune checkpoints and tumour metabolism as approaches that might enable further improvements in the outcomes of patients with cancer, either as monotherapies or in combination with existing agents. Key points Immune-checkpoint inhibitors (ICIs) have revolutionized cancer therapy, although clinically approved agents are currently restricted to those targeting PD-1/PD-L1 or CTLA4. The addition of therapies targeting a wider range of immune checkpoints will enable improved outcomes. Among co-inhibitory immune checkpoints, targets include LAG3, TIM3, TIGIT and BTLA, with agents targeting LAG3 currently the most advanced in terms of clinical development. Antibodies against co-stimulatory targets, such as GITR, OX40, 41BB and ICOS, have considerable potential to complement the currently available ICIs, although optimizing the timing of administration will be important. Changes in tumour cell and T cell metabolism are a source of additional targets, both of which have highly promising preclinical data available, albeit with only modest success in clinical trials thus far. |
| Author | Wolchok, Jedd D. Kraehenbuehl, Lukas Weng, Chien-Huan Eghbali, Shabnam Merghoub, Taha |
| Author_xml | – sequence: 1 givenname: Lukas orcidid: 0000-0001-5411-5661 surname: Kraehenbuehl fullname: Kraehenbuehl, Lukas organization: Ludwig Collaborative and Swim Across America Laboratory, MSK, Parker Institute for Cancer Immunotherapy, MSK, Human Oncology and Pathogenesis Program, MSK, Department of Medicine, MSK – sequence: 2 givenname: Chien-Huan orcidid: 0000-0002-5478-9188 surname: Weng fullname: Weng, Chien-Huan organization: Ludwig Collaborative and Swim Across America Laboratory, MSK, Parker Institute for Cancer Immunotherapy, MSK, Human Oncology and Pathogenesis Program, MSK – sequence: 3 givenname: Shabnam orcidid: 0000-0002-1326-0050 surname: Eghbali fullname: Eghbali, Shabnam organization: Ludwig Collaborative and Swim Across America Laboratory, MSK, Parker Institute for Cancer Immunotherapy, MSK, Human Oncology and Pathogenesis Program, MSK, Weill Cornell Medicine – sequence: 4 givenname: Jedd D. orcidid: 0000-0001-6718-2222 surname: Wolchok fullname: Wolchok, Jedd D. organization: Ludwig Collaborative and Swim Across America Laboratory, MSK, Parker Institute for Cancer Immunotherapy, MSK, Human Oncology and Pathogenesis Program, MSK, Department of Medicine, MSK, Weill Cornell Medicine – sequence: 5 givenname: Taha orcidid: 0000-0002-1518-5111 surname: Merghoub fullname: Merghoub, Taha email: merghout@mskcc.org organization: Ludwig Collaborative and Swim Across America Laboratory, MSK, Parker Institute for Cancer Immunotherapy, MSK, Human Oncology and Pathogenesis Program, MSK, Department of Medicine, MSK, Weill Cornell Medicine |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34580473$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kUtLxDAUhYOM-Bj9Ay6k4MZN9abNo7MUGR8giKDrkCbpTKVNxiRF-u_NOKOCi1mEeyHfSc695xhNrLMGoTMMVxjK6joQTDnOoUgHKC1yvoeOMKeznPCqmPz2nByi4xDeARgjvDxAhyWhFaT2CL3M7VJa1dpF1vb9YF1cGi9XY9baTKUL47N6zKL0CxPXkOmNX_zRvdNDJ6PzY7aScfkpx3CC9hvZBXO6rVP0djd_vX3In57vH29vnnJFCI45azQ1vKkMUbMSdN0QWVCtFa8x0zPKlQKoWdM0gFmBoeKyqhglTCudBgZVTtHl5t2Vdx-DCVH0bVCm66Q1bgiioGlwSoCThF78Q9_d4G1yJwqGMcCMYZao8y011L3RYuXbXvpR_CwrAcUGUN6F4E3zi2AQ60TEJhGRDIrvRARPouqfSLVRxtbZ6GXb7ZaWG2lI_9iF8X-2d6i-AH2qn-4 |
| CitedBy_id | crossref_primary_10_1016_j_autrev_2024_103579 crossref_primary_10_1007_s44272_023_00002_8 crossref_primary_10_1146_annurev_cancerbio_062822_024810 crossref_primary_10_3390_bioengineering11030264 crossref_primary_10_1002_adhm_202401223 crossref_primary_10_1016_j_canlet_2024_217214 crossref_primary_10_1111_jcmm_70525 crossref_primary_10_1038_s42003_023_05080_x crossref_primary_10_3390_vaccines10040540 crossref_primary_10_3389_fmed_2024_1233913 crossref_primary_10_1186_s40364_025_00807_w crossref_primary_10_1080_14756366_2022_2089665 crossref_primary_10_1038_s41419_023_06389_5 crossref_primary_10_1111_pin_13284 crossref_primary_10_3390_cancers15041324 crossref_primary_10_1186_s40364_025_00784_0 crossref_primary_10_3390_pharmaceutics14071358 crossref_primary_10_1002_advs_202414162 crossref_primary_10_1053_j_seminhematol_2023_02_002 crossref_primary_10_1016_j_molimm_2025_03_015 crossref_primary_10_1002_advs_202506282 crossref_primary_10_1016_j_bioactmat_2024_05_014 crossref_primary_10_1007_s12672_023_00672_9 crossref_primary_10_1186_s12916_023_02960_1 crossref_primary_10_1186_s12964_024_01848_8 crossref_primary_10_1016_j_beem_2024_101931 crossref_primary_10_1016_j_jcis_2025_02_012 crossref_primary_10_1016_j_ucl_2023_01_012 crossref_primary_10_1186_s12964_025_02161_8 crossref_primary_10_3389_fimmu_2025_1630940 crossref_primary_10_3390_cancers16112034 crossref_primary_10_1161_CIRCRESAHA_124_323816 crossref_primary_10_1038_s41467_024_55207_9 crossref_primary_10_1038_s41598_024_60819_8 crossref_primary_10_1038_s44318_024_00217_y crossref_primary_10_1016_j_cej_2025_167274 crossref_primary_10_1016_j_pharmthera_2022_108239 crossref_primary_10_3389_fimmu_2024_1357333 crossref_primary_10_1016_j_biomaterials_2024_122703 crossref_primary_10_1016_j_bmc_2025_118375 crossref_primary_10_1007_s00395_024_01077_7 crossref_primary_10_1080_1061186X_2025_2522868 crossref_primary_10_3389_fimmu_2023_1208631 crossref_primary_10_1016_j_ccr_2024_216006 crossref_primary_10_3389_fimmu_2023_1228581 crossref_primary_10_3389_fgene_2022_1078790 crossref_primary_10_1007_s12672_025_02639_4 crossref_primary_10_3389_fimmu_2024_1424259 crossref_primary_10_1038_s41698_025_01052_y crossref_primary_10_3389_fphar_2023_1285343 crossref_primary_10_1002_smll_202306378 crossref_primary_10_3389_fimmu_2024_1469096 crossref_primary_10_1097_MD_0000000000035722 crossref_primary_10_1002_anie_202416426 crossref_primary_10_1016_j_ijid_2023_11_021 crossref_primary_10_1002_advs_202500806 crossref_primary_10_1002_advs_202411813 crossref_primary_10_1007_s00520_024_08525_z crossref_primary_10_1016_j_molstruc_2024_141213 crossref_primary_10_1111_cas_15497 crossref_primary_10_3389_fphar_2023_1333507 crossref_primary_10_1016_j_cclet_2025_110995 crossref_primary_10_1016_j_cellimm_2023_104782 crossref_primary_10_2174_0109298673260837231120101508 crossref_primary_10_3389_fimmu_2022_878194 crossref_primary_10_1016_j_bone_2024_117328 crossref_primary_10_1038_s41573_022_00415_5 crossref_primary_10_3390_jcm14020527 crossref_primary_10_3390_ijms25179423 crossref_primary_10_1002_smtd_202300347 crossref_primary_10_1097_CJI_0000000000000511 crossref_primary_10_3390_v14030581 crossref_primary_10_1002_adhm_202402127 crossref_primary_10_1002_advs_202302131 crossref_primary_10_1002_EXP_20210146 crossref_primary_10_3389_fphar_2023_1127557 crossref_primary_10_1016_j_canlet_2023_216180 crossref_primary_10_1038_s41418_024_01432_0 crossref_primary_10_1159_000531175 crossref_primary_10_1016_j_phrs_2023_106850 crossref_primary_10_3390_diseases10030060 crossref_primary_10_1002_adfm_202500196 crossref_primary_10_1016_j_jconrel_2025_113988 crossref_primary_10_3389_fimmu_2023_1104771 crossref_primary_10_3389_fchem_2022_946574 crossref_primary_10_1136_jitc_2024_008942 crossref_primary_10_1186_s12951_025_03129_z crossref_primary_10_3390_cancers14123024 crossref_primary_10_1016_j_jconrel_2023_02_040 crossref_primary_10_1186_s12935_023_03136_w crossref_primary_10_7717_peerj_15136 crossref_primary_10_1007_s00262_023_03384_9 crossref_primary_10_1158_1078_0432_CCR_22_1471 crossref_primary_10_1186_s40164_023_00428_9 crossref_primary_10_1158_2326_6066_CIR_24_1055 crossref_primary_10_34133_bmr_0015 crossref_primary_10_1177_03000605241287015 crossref_primary_10_1002_ange_202416426 crossref_primary_10_1007_s13105_024_01020_3 crossref_primary_10_1002_adfm_202205371 crossref_primary_10_1097_MD_0000000000035837 crossref_primary_10_1186_s12967_024_05552_6 crossref_primary_10_3389_fmolb_2022_861380 crossref_primary_10_1016_j_cell_2023_03_006 crossref_primary_10_3390_pharmaceutics14081698 crossref_primary_10_1038_s41568_024_00706_6 crossref_primary_10_1093_jnci_djad125 crossref_primary_10_3389_fendo_2023_1217669 crossref_primary_10_1016_j_ymthe_2023_01_017 crossref_primary_10_1016_j_actbio_2025_05_027 crossref_primary_10_1007_s00262_025_04098_w crossref_primary_10_1002_advs_202400702 crossref_primary_10_1016_j_csbj_2023_11_014 crossref_primary_10_1177_10781552231171881 crossref_primary_10_3390_cells11243991 crossref_primary_10_3390_pharmaceutics17060682 crossref_primary_10_1016_j_apsb_2024_03_022 crossref_primary_10_3390_ph17121713 crossref_primary_10_3389_fonc_2022_830546 crossref_primary_10_1016_j_addr_2022_114308 crossref_primary_10_3390_biomedicines13030664 crossref_primary_10_3390_jcm11236892 crossref_primary_10_1016_j_hoc_2023_02_008 crossref_primary_10_1097_CM9_0000000000002768 crossref_primary_10_1186_s12967_025_06768_w crossref_primary_10_1186_s12885_023_11415_y crossref_primary_10_1016_j_jconrel_2024_09_007 crossref_primary_10_1186_s13073_025_01465_1 crossref_primary_10_62347_KZOQ9722 crossref_primary_10_1055_s_0043_1776761 crossref_primary_10_1038_s41392_023_01317_7 crossref_primary_10_1002_adma_202405673 crossref_primary_10_3389_fimmu_2025_1632378 crossref_primary_10_1158_0008_5472_CAN_24_4383 crossref_primary_10_1038_s41577_024_01026_4 crossref_primary_10_1186_s12951_024_03059_2 crossref_primary_10_1016_j_canlet_2024_216758 crossref_primary_10_1126_scitranslmed_adg6752 crossref_primary_10_1007_s11051_023_05792_5 crossref_primary_10_1186_s12885_025_14089_w crossref_primary_10_1097_MD_0000000000036598 crossref_primary_10_1002_adma_202308774 crossref_primary_10_1038_s41571_024_00869_z crossref_primary_10_3390_ijms26115394 crossref_primary_10_3389_fendo_2023_1256132 crossref_primary_10_1007_s12072_023_10572_3 crossref_primary_10_1002_cac2_12486 crossref_primary_10_1016_j_freeradbiomed_2022_10_004 crossref_primary_10_1002_cti2_1506 crossref_primary_10_1016_j_bioorg_2025_108158 crossref_primary_10_1016_j_bcp_2024_116162 crossref_primary_10_3389_fcimb_2022_872019 crossref_primary_10_3390_jcm12247531 crossref_primary_10_3389_fimmu_2025_1644391 crossref_primary_10_3389_fimmu_2023_1219487 crossref_primary_10_1007_s11684_023_1012_z crossref_primary_10_3389_fimmu_2023_1332814 crossref_primary_10_1186_s40164_023_00378_2 crossref_primary_10_1093_lifemedi_lnae031 crossref_primary_10_1186_s12929_023_00952_0 crossref_primary_10_1016_j_bbrc_2025_151347 crossref_primary_10_3389_fphar_2023_1184703 crossref_primary_10_3390_cancers16010047 crossref_primary_10_1089_mab_2022_0002 crossref_primary_10_3389_fimmu_2023_1132601 crossref_primary_10_1002_advs_202510004 crossref_primary_10_1002_cbf_3934 crossref_primary_10_1089_mab_2022_0019 crossref_primary_10_1038_s41571_023_00782_x crossref_primary_10_3390_ijms222413360 crossref_primary_10_1016_j_biopha_2024_116317 crossref_primary_10_1016_j_bbcan_2025_189433 crossref_primary_10_1038_s41467_025_60448_3 crossref_primary_10_1089_mab_2022_0010 crossref_primary_10_2147_IJN_S479434 crossref_primary_10_1016_j_cej_2025_161104 crossref_primary_10_1089_mab_2022_0016 crossref_primary_10_1016_j_jconrel_2025_113816 crossref_primary_10_2147_IJN_S457782 crossref_primary_10_1016_j_intimp_2022_108798 crossref_primary_10_1186_s12951_025_03154_y crossref_primary_10_1126_sciimmunol_adn9633 crossref_primary_10_2217_fon_2023_0962 crossref_primary_10_3390_cancers16091628 crossref_primary_10_3390_cancers15143733 crossref_primary_10_1089_mab_2022_0013 crossref_primary_10_1042_BSR20221680 crossref_primary_10_3389_fimmu_2023_1092401 crossref_primary_10_1016_j_ccr_2025_216674 crossref_primary_10_1038_s41467_024_49825_6 crossref_primary_10_1186_s12885_025_14519_9 crossref_primary_10_1016_j_jcis_2024_10_156 crossref_primary_10_1155_2022_9365046 crossref_primary_10_1016_j_nantod_2023_101987 crossref_primary_10_1038_s44321_024_00026_0 crossref_primary_10_1016_j_apsb_2024_10_016 crossref_primary_10_1136_jitc_2024_009893 crossref_primary_10_1186_s12951_022_01561_z crossref_primary_10_1038_s41573_024_00896_6 crossref_primary_10_1016_j_cej_2024_154506 crossref_primary_10_32604_or_2023_046712 crossref_primary_10_1186_s12876_025_03878_z crossref_primary_10_1016_j_ebiom_2023_104801 crossref_primary_10_1186_s12943_024_02179_5 crossref_primary_10_1007_s00210_025_04133_8 crossref_primary_10_1080_13543784_2022_2078191 crossref_primary_10_1186_s12943_022_01649_y crossref_primary_10_1038_s41467_023_44466_7 crossref_primary_10_1186_s12951_025_03669_4 crossref_primary_10_1002_advs_202401182 crossref_primary_10_1038_s43018_024_00892_0 crossref_primary_10_1080_08998280_2022_2114129 crossref_primary_10_1089_ars_2022_0047 crossref_primary_10_1016_j_ijpharm_2024_125004 crossref_primary_10_1186_s40364_023_00465_w crossref_primary_10_1002_adma_202309667 crossref_primary_10_1016_j_ajpath_2022_06_015 crossref_primary_10_1186_s13561_025_00656_1 crossref_primary_10_1038_s41467_024_49595_1 crossref_primary_10_1186_s40364_023_00508_2 crossref_primary_10_1002_cam4_4668 crossref_primary_10_1007_s10753_025_02298_1 crossref_primary_10_1016_j_ccell_2025_07_002 crossref_primary_10_3390_biology13050307 crossref_primary_10_1038_s41571_022_00689_z crossref_primary_10_1016_j_jss_2025_02_001 crossref_primary_10_3389_fimmu_2022_854883 crossref_primary_10_1016_j_bcp_2025_117333 crossref_primary_10_1080_2162402X_2022_2081010 crossref_primary_10_1186_s12885_023_11534_6 crossref_primary_10_1016_j_ejca_2023_03_010 crossref_primary_10_3390_cells11182881 crossref_primary_10_3389_fonc_2025_1532924 crossref_primary_10_1016_j_mtbio_2025_101826 crossref_primary_10_1093_oncolo_oyae154 crossref_primary_10_3390_genes14081599 crossref_primary_10_1186_s12967_022_03646_7 crossref_primary_10_1016_j_hrcr_2023_04_007 crossref_primary_10_1158_2159_8290_CD_24_1232 crossref_primary_10_1186_s12885_025_13479_4 crossref_primary_10_3389_fbioe_2023_1140436 crossref_primary_10_1089_mab_2024_0002 crossref_primary_10_1177_17588359251324882 crossref_primary_10_1111_hel_12925 crossref_primary_10_3389_fonc_2023_1307924 crossref_primary_10_1093_oncolo_oyad193 crossref_primary_10_1002_mba2_70024 crossref_primary_10_1002_adma_202307263 crossref_primary_10_3390_ijms25073987 crossref_primary_10_1016_j_ejps_2024_106959 crossref_primary_10_1016_j_isci_2023_107881 crossref_primary_10_1016_j_carpta_2025_100956 crossref_primary_10_1186_s12885_023_10755_z crossref_primary_10_1016_j_ccr_2023_215540 crossref_primary_10_1038_s41590_022_01132_2 crossref_primary_10_1177_03008916241229649 crossref_primary_10_3389_fimmu_2023_1085476 crossref_primary_10_1016_j_canlet_2022_216007 crossref_primary_10_1038_s41575_024_01019_7 crossref_primary_10_1002_advs_202410011 crossref_primary_10_1186_s12935_023_03065_8 crossref_primary_10_1038_s41467_024_47256_x crossref_primary_10_3390_cancers14030680 crossref_primary_10_1016_j_isci_2023_107894 crossref_primary_10_1186_s13148_021_01221_3 crossref_primary_10_3389_fonc_2024_1381381 crossref_primary_10_1016_j_it_2024_12_002 crossref_primary_10_1038_s43018_024_00744_x crossref_primary_10_3389_fmed_2024_1403171 crossref_primary_10_3389_frhem_2023_1279863 crossref_primary_10_3390_cancers15153836 crossref_primary_10_1016_j_nxmate_2025_100913 crossref_primary_10_1016_j_cis_2023_103007 crossref_primary_10_1186_s12885_023_10766_w crossref_primary_10_1016_j_biomaterials_2025_123669 crossref_primary_10_3390_cancers15010246 crossref_primary_10_1002_smll_202508241 crossref_primary_10_1016_j_intimp_2023_109882 crossref_primary_10_3389_fimmu_2022_1070367 crossref_primary_10_1007_s00259_024_06911_7 crossref_primary_10_1016_j_canlet_2024_216908 crossref_primary_10_1016_j_apsb_2024_05_013 crossref_primary_10_3389_fcell_2023_1173803 crossref_primary_10_3390_cancers16173071 crossref_primary_10_1186_s12951_022_01719_9 crossref_primary_10_1002_advs_202507904 crossref_primary_10_1186_s12967_023_04804_1 crossref_primary_10_1002_lary_31568 crossref_primary_10_3389_fonc_2024_1378095 crossref_primary_10_1002_adfm_202214824 crossref_primary_10_1002_btm2_10628 crossref_primary_10_3390_s24010173 crossref_primary_10_1007_s12672_025_03356_8 crossref_primary_10_3390_antiox12122131 crossref_primary_10_3390_cancers15153818 crossref_primary_10_3389_fimmu_2022_923481 crossref_primary_10_1097_MCC_0000000000000978 crossref_primary_10_1016_j_esmogo_2023_100039 crossref_primary_10_3390_medicina58101439 crossref_primary_10_3389_fonc_2022_809589 crossref_primary_10_1002_chem_202302948 crossref_primary_10_1186_s12967_025_06606_z crossref_primary_10_1016_j_gene_2022_146765 crossref_primary_10_3390_cancers15010109 crossref_primary_10_1016_j_heliyon_2023_e22656 crossref_primary_10_1002_advs_202404961 crossref_primary_10_1002_INMD_20240005 crossref_primary_10_1016_j_ymthe_2023_12_011 crossref_primary_10_1161_CIRCULATIONAHA_123_067189 crossref_primary_10_1158_0008_5472_CAN_24_0940 crossref_primary_10_1007_s00044_023_03168_x crossref_primary_10_1016_j_smim_2023_101733 crossref_primary_10_1016_j_cej_2025_163579 crossref_primary_10_1016_j_jconrel_2024_09_044 crossref_primary_10_1038_s41598_025_17987_y crossref_primary_10_1016_j_fmre_2025_08_009 crossref_primary_10_1186_s12943_023_01800_3 crossref_primary_10_1007_s10072_023_07190_0 crossref_primary_10_1016_S1470_2045_24_00199_2 crossref_primary_10_1002_advs_202402678 crossref_primary_10_3390_ijms241310873 crossref_primary_10_3390_ph16070935 crossref_primary_10_3389_fonc_2025_1454546 crossref_primary_10_1016_j_pccm_2024_12_001 crossref_primary_10_1016_j_ejpb_2024_114410 crossref_primary_10_1021_jacs_4c12552 crossref_primary_10_3389_fimmu_2022_880959 crossref_primary_10_1002_adma_202311574 crossref_primary_10_1146_annurev_cancerbio_061521_093717 crossref_primary_10_3389_fonc_2025_1464578 crossref_primary_10_1080_17410541_2024_2447224 crossref_primary_10_3390_cancers15030914 crossref_primary_10_1016_j_bulcan_2023_03_021 crossref_primary_10_3389_fphys_2023_1103354 crossref_primary_10_1080_13685538_2023_2183947 crossref_primary_10_1038_s41598_022_12301_6 crossref_primary_10_1016_j_phrs_2023_107022 crossref_primary_10_1084_jem_20241433 crossref_primary_10_3390_cancers17122011 crossref_primary_10_1002_adma_202303979 crossref_primary_10_1007_s11864_024_01200_9 crossref_primary_10_3390_biomedicines10092210 crossref_primary_10_3390_cancers16244271 crossref_primary_10_3389_fonc_2022_753234 crossref_primary_10_1186_s11658_023_00461_w crossref_primary_10_1016_j_intimp_2022_109335 crossref_primary_10_3390_cancers15123159 crossref_primary_10_1038_s41541_025_01084_2 crossref_primary_10_1038_s41392_023_01522_4 crossref_primary_10_1002_eji_202350493 crossref_primary_10_3390_cancers14194657 crossref_primary_10_1002_advs_202405845 crossref_primary_10_1002_adfm_202209056 crossref_primary_10_1016_j_nantod_2025_102691 crossref_primary_10_3390_cancers16244146 crossref_primary_10_1002_smll_202301281 crossref_primary_10_3389_fphar_2022_922029 crossref_primary_10_1016_j_cej_2025_164657 crossref_primary_10_1016_j_critrevonc_2023_104204 crossref_primary_10_1016_j_jconrel_2023_12_018 crossref_primary_10_1016_j_matdes_2022_110738 crossref_primary_10_1097_CM9_0000000000002536 crossref_primary_10_2217_imt_2023_0307 crossref_primary_10_3389_fimmu_2023_1105180 crossref_primary_10_1002_mog2_70024 crossref_primary_10_1016_j_cellsig_2024_111054 crossref_primary_10_1038_s41392_025_02219_6 crossref_primary_10_1038_s41571_022_00718_x crossref_primary_10_1016_j_pccm_2023_08_002 crossref_primary_10_1136_jitc_2023_008078 crossref_primary_10_1002_mco2_355 crossref_primary_10_1158_2159_8290_CD_22_0907 crossref_primary_10_1002_adma_202301455 crossref_primary_10_1002_adma_202304845 crossref_primary_10_1007_s00262_025_04085_1 crossref_primary_10_1172_JCI161483 crossref_primary_10_1038_s41392_025_02190_2 crossref_primary_10_1038_s41467_024_50478_8 crossref_primary_10_1136_gutjnl_2022_329349 crossref_primary_10_1016_j_tranon_2023_101735 crossref_primary_10_1111_jcmm_18470 crossref_primary_10_1186_s12943_025_02412_9 crossref_primary_10_1002_advs_202409533 crossref_primary_10_1016_j_carbpol_2025_123416 crossref_primary_10_1016_j_intimp_2025_114261 crossref_primary_10_1016_j_canlet_2024_217062 crossref_primary_10_1186_s12943_024_01956_6 crossref_primary_10_1016_j_medj_2025_100669 crossref_primary_10_1002_jev2_70068 crossref_primary_10_1038_s41467_023_39119_8 crossref_primary_10_1002_jhet_4907 crossref_primary_10_3390_cancers15030824 crossref_primary_10_1042_EBC20220016 crossref_primary_10_1186_s12885_024_12994_0 crossref_primary_10_3389_fimmu_2023_1325615 crossref_primary_10_1038_s41590_022_01140_2 crossref_primary_10_3389_fendo_2022_864253 crossref_primary_10_1007_s12026_024_09458_9 crossref_primary_10_1007_s12032_023_02235_y crossref_primary_10_1021_acs_nanolett_5c02670 crossref_primary_10_1212_CON_0000000000001362 crossref_primary_10_1007_s00262_024_03704_7 crossref_primary_10_3389_fimmu_2024_1260191 crossref_primary_10_1097_JS9_0000000000001901 crossref_primary_10_1186_s12967_023_04589_3 crossref_primary_10_1016_j_cej_2024_151709 crossref_primary_10_3390_cancers14174167 crossref_primary_10_1096_fj_202301018R crossref_primary_10_3389_fimmu_2025_1604216 crossref_primary_10_1016_j_ccell_2024_09_010 crossref_primary_10_3389_fimmu_2022_811200 crossref_primary_10_1016_j_intimp_2023_110243 crossref_primary_10_1002_1878_0261_13474 crossref_primary_10_2147_IJN_S440332 crossref_primary_10_1038_s41467_023_36769_6 crossref_primary_10_1016_j_cej_2024_158682 crossref_primary_10_3390_antib11030046 crossref_primary_10_3390_antib11030047 crossref_primary_10_1002_smll_202203227 crossref_primary_10_1016_j_exger_2024_112552 crossref_primary_10_1038_s41423_023_01093_y crossref_primary_10_1186_s12920_024_01863_1 crossref_primary_10_3390_ijms24065643 crossref_primary_10_1038_s41564_024_01695_w crossref_primary_10_1186_s12957_023_03212_5 crossref_primary_10_1038_s41598_022_17645_7 crossref_primary_10_1186_s40001_023_01583_9 crossref_primary_10_1186_s12943_022_01672_z crossref_primary_10_3389_fmolb_2022_930207 crossref_primary_10_1016_j_cyto_2024_156675 crossref_primary_10_1002_adma_202303542 crossref_primary_10_1016_j_ccell_2025_04_005 crossref_primary_10_1038_s41575_022_00704_9 crossref_primary_10_3389_fimmu_2023_1121285 crossref_primary_10_1038_s41556_024_01428_5 crossref_primary_10_1177_15353702221089910 crossref_primary_10_1016_j_jconrel_2024_10_017 crossref_primary_10_1089_lap_2024_0164 crossref_primary_10_1016_j_ymthe_2024_12_007 crossref_primary_10_1016_j_actbio_2024_07_034 crossref_primary_10_1016_j_canlet_2024_217399 crossref_primary_10_1007_s12185_023_03586_y crossref_primary_10_1038_s43018_024_00746_9 crossref_primary_10_1016_j_canlet_2024_217152 crossref_primary_10_1016_j_thorsurg_2025_07_008 crossref_primary_10_3390_cancers15235495 crossref_primary_10_1038_s41571_025_01035_9 crossref_primary_10_7717_peerj_15799 crossref_primary_10_3389_fimmu_2022_938470 crossref_primary_10_1002_adma_202209379 crossref_primary_10_3892_or_2023_8553 crossref_primary_10_1038_s41467_024_48397_9 crossref_primary_10_1016_j_identj_2024_04_005 crossref_primary_10_1016_j_ccell_2025_03_005 crossref_primary_10_1016_j_intimp_2023_110418 crossref_primary_10_3389_fimmu_2023_1227797 crossref_primary_10_1039_D4NR01497A crossref_primary_10_1186_s12967_023_04064_z crossref_primary_10_1002_smll_202504487 crossref_primary_10_1016_j_intimp_2022_109383 crossref_primary_10_1002_advs_202507975 crossref_primary_10_3389_fimmu_2022_868325 crossref_primary_10_1016_j_cej_2023_147118 crossref_primary_10_1002_cac2_12636 crossref_primary_10_3389_fimmu_2025_1554499 crossref_primary_10_1016_j_imbio_2022_152317 crossref_primary_10_1080_00365521_2023_2281252 crossref_primary_10_1080_1750743X_2025_2561398 crossref_primary_10_1002_wnan_1906 crossref_primary_10_1136_jitc_2024_010024 crossref_primary_10_3390_ijms24043525 crossref_primary_10_1016_j_medj_2024_09_010 crossref_primary_10_1002_adma_202300171 crossref_primary_10_3389_fimmu_2022_1013186 crossref_primary_10_1002_smll_202307310 crossref_primary_10_1016_j_semcancer_2023_01_005 crossref_primary_10_3389_fcell_2022_913684 crossref_primary_10_1021_jacs_5c02025 crossref_primary_10_1186_s13036_025_00536_6 crossref_primary_10_1007_s12035_025_04746_3 crossref_primary_10_1016_j_apsb_2022_11_001 crossref_primary_10_1097_MD_0000000000038387 crossref_primary_10_1038_s41392_024_01826_z crossref_primary_10_1016_j_cellsig_2023_110976 crossref_primary_10_1080_2162402X_2025_2507856 crossref_primary_10_1186_s12951_023_02132_6 crossref_primary_10_1016_j_ajo_2024_10_001 crossref_primary_10_3390_ijms252413426 crossref_primary_10_1016_j_jep_2024_117984 crossref_primary_10_3389_fimmu_2024_1255825 crossref_primary_10_3389_fimmu_2025_1523436 crossref_primary_10_1007_s12094_023_03282_7 crossref_primary_10_1007_s12672_024_00974_6 crossref_primary_10_1186_s12951_023_02231_4 crossref_primary_10_1002_advs_202308734 crossref_primary_10_3389_fmolb_2023_1261273 crossref_primary_10_1016_j_tranon_2023_101828 crossref_primary_10_1002_cam4_6174 crossref_primary_10_1016_j_intimp_2024_111717 crossref_primary_10_1097_MD_0000000000042406 crossref_primary_10_1038_s41598_025_88966_6 |
| Cites_doi | 10.1016/j.immuni.2004.08.010 10.1038/415536a 10.1126/sciimmunol.abc2728 10.1056/NEJMra1703481 10.1158/1078-0432.CCR-20-1830 10.1038/s41568-020-0285-7 10.1200/JCO.2021.39.3_suppl.404 10.1084/jem.176.2.327 10.1038/s41416-019-0650-z 10.1158/1538-7445.AM2017-4703 10.1093/annonc/mdz252.011 10.3389/fonc.2018.00436 10.1038/nature14404 10.1126/science.aaa1348 10.1200/JCO.2020.38.15_suppl.3100 10.1038/s41577-019-0224-6 10.1038/nri3405 10.1038/s41416-020-0994-4 10.1038/nrc.2017.117 10.4049/jimmunol.155.3.1151 10.1158/1078-0432.CCR-09-0265 10.1084/jem.171.5.1393 10.1158/0008-5472.CAN-11-1620 10.1016/j.cell.2017.07.024 10.1186/s13578-020-00396-1 10.1136/jitc-2020-001014 10.1126/science.342.6165.1432 10.1158/0008-5472.CAN-16-1439 10.1126/sciimmunol.aat7061 10.1158/2326-6066.CIR-13-0086 10.1038/s41467-021-21047-0 10.1038/s41577-019-0140-9 10.1016/j.it.2013.10.001 10.1016/S1470-2045(19)30274-8 10.1001/jama.1994.03510360033032 10.1177/1758835920937612 10.1158/1538-7445.AM2020-CT150 10.1016/j.bbrc.2003.11.070 10.1016/j.canlet.2013.06.026 10.1038/nri3740 10.1158/0008-5472.CAN-10-0283 10.1111/imr.12520 10.1016/j.ejca.2016.06.028 10.1002/eji.200323382 10.1158/0008-5472.CAN-17-2460 10.1158/0008-5472.CAN-13-2690 10.1038/s41571-020-0382-2 10.1158/1078-0432.CCR-19-0289 10.1158/1538-7445.AM2018-1699 10.1038/s41590-020-0725-2 10.1126/science.1129139 10.1016/j.immuni.2017.12.012 10.1016/j.cell.2018.11.010 10.1093/annonc/mdw410 10.1007/s10735-013-9495-6 10.1200/JCO.2014.58.3377 10.1073/pnas.2020606118 10.1038/ni.2035 10.1056/NEJMoa1112824 10.1016/j.annonc.2020.08.2278 10.1038/s41568-021-00346-0 10.1056/NEJM200010053431407 10.3390/cancers12030738 10.1200/JCO.2018.36.15_suppl.3029 10.1158/1078-0432.CCR-13-0945 10.1200/JCO.2020.38.15_suppl.9503 10.1200/JCO.2000.18.12.2444 10.1038/cddis.2015.162 10.1186/s40425-019-0815-6 10.1111/j.1432-1033.1984.tb08263.x 10.1158/1538-7445.AM2017-3643 10.1002/hep.30881 10.1016/j.cels.2017.12.014 10.1016/S0022-5347(17)58737-6 10.1038/s41467-021-21383-1 10.1200/JCO.2014.56.2736 10.1056/NEJMoa1910836 10.1158/2326-6066.CIR-20-0034 10.3389/fimmu.2019.00453 10.1097/COC.0000000000000239 10.1038/ni.1674 10.1002/mc.20702 10.3389/fimmu.2019.00617 10.1158/1078-0432.CCR-06-1166 10.1016/j.it.2016.10.002 10.1038/srep15659 10.1186/s40425-019-0570-8 10.1200/JCO.2018.36.15_suppl.3000 10.1126/science.aah3374 10.1073/pnas.1106550108 10.1111/cei.13407 10.1126/science.2413547 10.1097/00000658-189112000-00015 10.4049/jimmunol.1900696 10.1038/ni1144 10.1056/NEJMoa1414428 10.1093/annonc/mdx440.011 10.1038/nrd.2018.75 10.1084/jem.20100619 10.1158/1078-0432.CCR-19-2958 10.1186/s13045-018-0667-4 10.1001/jamaoncol.2019.3848 10.2217/imt-2017-0024 10.1038/s41586-020-03045-2 10.1158/0008-5472.CAN-06-4447 10.1016/j.cell.2018.11.006 10.1038/s41591-019-0420-8 10.1016/j.neo.2017.12.002 10.4049/jimmunol.1103627 10.3390/cells9030785 10.1186/s40425-018-0360-8 10.1111/imr.12849 10.1038/s41586-021-03326-4 10.1056/NEJMoa1003466 10.1158/1078-0432.CCR-09-0068 10.1186/s40425-018-0407-x 10.4049/jimmunol.173.11.6806 10.1038/nature13848 10.1038/s41571-018-0046-7 10.1186/s13045-018-0582-8 10.1038/s41422-020-0379-5 10.1084/jem.20082205 10.1111/imr.12519 10.1172/JCI128562 10.1016/j.semcancer.2019.06.021 10.1002/cncr.33133 10.1038/ni.3415 10.1038/s41467-019-10088-1 10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E 10.1056/NEJMoa1709684 10.1158/2326-6066.CIR-16-0103 10.1200/JCO.2020.38.4_suppl.523 10.1038/nrurol.2018.32 10.1111/j.1600-065X.1998.tb01205.x 10.4049/jimmunol.136.9.3282 10.1093/intimm/dxh059 10.1038/s41577-018-0044-0 10.1038/s41590-018-0132-0 10.1016/j.annonc.2020.08.1714 10.1158/2326-6066.CIR-14-0150 10.4049/jimmunol.154.11.5757 10.1186/s12943-021-01348-0 10.1084/jem.189.9.1363 10.1073/pnas.94.12.6216 10.4110/in.2020.20.e3 10.1200/JCO.2018.36.15_suppl.3012 10.1158/1538-7445.AM2019-CT183 10.1001/jamanetworkopen.2019.2535 10.1158/0008-5472.CAN-11-1782 10.1016/S1074-7613(02)00323-0 10.1038/s41577-019-0203-y 10.1158/1078-0432.CCR-20-0452 10.1016/j.semcancer.2006.07.002 10.1158/2326-6066.CIR-19-0115 10.1158/1078-0432.CCR-20-0113 10.1158/1078-0432.CCR-17-1922 10.1038/s41590-020-00834-9 10.1158/1078-0432.CCR-17-0186 10.1158/1078-0432.CCR-16-2677 10.1172/jci.insight.96976 |
| ContentType | Journal Article |
| Copyright | Springer Nature Limited 2021 2021. Springer Nature Limited. Springer Nature Limited 2021. |
| Copyright_xml | – notice: Springer Nature Limited 2021 – notice: 2021. Springer Nature Limited. – notice: Springer Nature Limited 2021. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7T5 7TM 7TO 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1038/s41571-021-00552-7 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection (subscription) ProQuest Central Natural Science Collection ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | ProQuest Central Student MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7RV name: Nursing & Allied Health Database url: https://search.proquest.com/nahs sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1759-4782 |
| EndPage | 50 |
| ExternalDocumentID | 34580473 10_1038_s41571_021_00552_7 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: P30 CA008748 |
| GroupedDBID | --- .XZ 0R~ 29M 39C 3V. 53G 70F 7RV 7X7 88E 8FI 8FJ AAEEF AARCD AAWTL AAWYQ AAYZH AAZLF ABAWZ ABJNI ABLJU ABUWG ACGFS ACPRK ADBBV AENEX AFKRA AFSHS AGAYW AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS ARMCB AXYYD BBNVY BENPR BHPHI BKEYQ BKKNO BPHCQ BVXVI CCPQU DB5 EBS EE. EJD EX3 EXGXG F5P FQGFK FSGXE FYUFA HCIFZ HMCUK HZ~ IAO IHR IHW INH INR ITC M1P M7P NAPCQ NNMJJ NXXTH O9- ODYON OVD PQQKQ PROAC PSQYO RNR RNT RNTTT SHXYY SIXXV SJN SNYQT SOJ TAOOD TBHMF TDRGL TEORI TSG UKHRP WOW AAYXX ABFSG ACSTC AEZWR AFANA AFHIU AGSTI AHWEU AIXLP ALPWD ATHPR CITATION CGR CUY CVF ECM EIF NFIDA NPM PHGZM PHGZT PJZUB PPXIY PQGLB 7T5 7TM 7TO 7XB 8FE 8FH 8FK AZQEC DWQXO GNUQQ H94 K9. LK8 PKEHL PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c441t-6fd5e7f8e4c930dbf4a25ddc7b16d957cc00b6fff01621087a886546dcd0210c3 |
| IEDL.DBID | 7RV |
| ISICitedReferencesCount | 604 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000701025500003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1759-4774 1759-4782 |
| IngestDate | Thu Oct 02 19:50:46 EDT 2025 Sat Nov 29 14:50:53 EST 2025 Mon Jul 21 05:59:25 EDT 2025 Sat Nov 29 06:26:59 EST 2025 Tue Nov 18 22:36:41 EST 2025 Fri Feb 21 02:37:38 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2021. Springer Nature Limited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c441t-6fd5e7f8e4c930dbf4a25ddc7b16d957cc00b6fff01621087a886546dcd0210c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0002-1518-5111 0000-0001-6718-2222 0000-0002-5478-9188 0000-0002-1326-0050 0000-0001-5411-5661 |
| PMID | 34580473 |
| PQID | 2611009616 |
| PQPubID | 536303 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_2577454074 proquest_journals_2611009616 pubmed_primary_34580473 crossref_primary_10_1038_s41571_021_00552_7 crossref_citationtrail_10_1038_s41571_021_00552_7 springer_journals_10_1038_s41571_021_00552_7 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-01 |
| PublicationDateYYYYMMDD | 2022-01-01 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Nature reviews. Clinical oncology |
| PublicationTitleAbbrev | Nat Rev Clin Oncol |
| PublicationTitleAlternate | Nat Rev Clin Oncol |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Duhen (CR66) 2021; 12 Postow, Sidlow, Hellmann (CR14) 2018; 378 Tahara-Hanaoka (CR121) 2004; 16 Chang, Pearce (CR134) 2016; 17 Chang, Chang, Chen, Lin, Lin (CR151) 2007; 13 Hahn, Gill, Pal, Agarwal (CR115) 2017; 9 Gutiérrez-Vázquez, Quintana (CR144) 2018; 48 Lakins (CR164) 2020; 26 Fuchs, Colonna (CR120) 2006; 16 Gavrieli, Watanabe, Loftin, Murphy, Murphy (CR127) 2003; 312 Mullard (CR147) 2018; 17 Waitz (CR29) 2012; 72 Rodriguez-Abreu (CR124) 2020; 38 Chen, Flies (CR35) 2013; 13 Schaer (CR61) 2013; 1 Wherry (CR83) 2011; 12 Triebel (CR95) 1990; 171 Speiser (CR87) 2014; 14 Felip (CR146) 2020; 38 Koundouros, Poulogiannis (CR154) 2020; 122 Morales, Eidinger, Bruce (CR4) 1976; 116 Wei (CR82) 2017; 170 Yu (CR91) 2009; 10 Andrews (CR104) 2020; 5 Zhao (CR58) 2010; 70 Jiang, Li, Zhu (CR129) 2015; 6 Gonzalez (CR60) 2017; 77 Turbitt, Buchta Rosean, Weber, Norian (CR163) 2020; 295 Rizvi (CR19) 2015; 348 El-Khoueiry (CR65) 2020; 38 Hirschhorn-Cymerman (CR63) 2009; 206 Chiappori (CR68) 2020; 8 Saxena, van der Burg, Melief, Bhardwaj (CR32) 2021; 21 Gonzalez (CR51) 2017; 77 Mayes, Hance, Hoos (CR40) 2018; 17 Sakaguchi, Sakaguchi, Asano, Itoh, Toda (CR46) 1995; 155 Schietinger, Greenberg (CR86) 2014; 35 Wolchok (CR7) 2018; 175 Zhang (CR119) 2018; 19 Long (CR148) 2019; 20 Mao (CR100) 2016; 353 Munn (CR142) 1999; 189 Zou, Tao, Li, Zhu (CR155) 2020; 10 Krebs (CR108) 2020; 8 Yap (CR80) 2018; 36 Schadendorf (CR12) 2015; 33 Ahn (CR125) 2020; 31 Buzzai (CR156) 2007; 67 Rosenberg (CR5) 1994; 271 Bruni, Angell, Galon (CR18) 2020; 20 Middleton (CR24) 2020; 123 Knee, Hewes, Brogdon (CR39) 2016; 67 Wolf, Anderson, Kuchroo (CR118) 2020; 20 Kvarnhammar (CR69) 2019; 7 Woo (CR105) 2012; 72 Spranger, Bao, Gajewski (CR20) 2015; 523 Xu (CR99) 2014; 74 Reznik (CR133) 2018; 6 Couzin-Frankel (CR6) 2013; 342 Gmunder, Lesslauer (CR78) 1984; 142 Chapman, Boothby, Chi (CR37) 2020; 20 Beck (CR44) 2021; 20 Nocentini (CR45) 1997; 94 Geva (CR54) 2018; 36 Postel-Vinay (CR64) 2020; 80 Frauwirth (CR131) 2002; 16 Spranger, Gajewski (CR21) 2018; 18 DiNatale, Schroeder, Perdew (CR153) 2011; 50 Galon (CR17) 2006; 313 Martin (CR77) 1986; 136 Coley (CR1) 1891; 14 Liu (CR152) 2013; 44 Ascierto (CR109) 2017; 28 Wang (CR150) 2013; 340 Jeong, Park (CR59) 2020; 20 Sedy (CR130) 2005; 6 Postow (CR15) 2015; 372 Hong (CR110) 2018; 36 Dewan (CR26) 2009; 15 Teijeira (CR132) 2019; 7 Guedan (CR73) 2018; 3 Tran (CR48) 2018; 6 Sainson (CR79) 2020; 8 Prigent, El Mir, Dreano, Triebel (CR106) 1999; 29 Maruhashi, Sugiura, Okazaki, Okazaki (CR94) 2020; 8 Jiang, Huang, Xu, Pu (CR42) 2021; 12 Heinhuis (CR53) 2020; 6 Scharping, Menk, Whetstone, Zeng, Delgoffe (CR157) 2017; 5 Monney (CR90) 2002; 415 Brignone, Escudier, Grygar, Marcu, Triebel (CR107) 2009; 15 Postow (CR27) 2012; 366 Geva (CR56) 2020; 126 Manieri, Chiang, Grogan (CR122) 2017; 38 Coyle, Cafferty, Vale, Langley (CR161) 2016; 27 Baixeras (CR97) 1992; 176 Huang (CR103) 2004; 21 von Andrian, Mackay (CR33) 2000; 343 Messenheimer (CR70) 2017; 23 Weiss (CR116) 2017; 5 Haslam, Prasad (CR10) 2019; 2 Chang (CR41) 2021; 118 Liu, Liu, Chen (CR112) 2018; 11 Kouo (CR98) 2015; 3 Wang (CR92) 2011; 208 Hodi (CR8) 2010; 363 Svane, Kjeldsen, Lorentzen, Martinenaite, Andersen (CR149) 2020; 31 Khair (CR165) 2019; 10 Curigliano (CR117) 2019; 79 Khalil (CR22) 2019; 129 Qi (CR74) 2019; 10 Marin-Acevedo (CR36) 2018; 11 Lozano, Dominguez-Villar, Kuchroo, Hafler (CR123) 2012; 188 Vaddepally, Kharel, Pandey, Garje, Chandra (CR9) 2020; 12 Das, Zhu, Kuchroo (CR111) 2017; 276 Borst, Ahrends, Bąbała, Melief, Kastenmüller (CR34) 2018; 18 Workman, Vignali (CR96) 2003; 33 Kirkwood (CR2) 2000; 18 Harjunpää, Guillerey (CR126) 2020; 200 Hwang, Pike, Royce, Mahal, Loeffler (CR28) 2018; 15 Wang (CR101) 2019; 176 Zappasodi (CR135) 2021; 591 Rischin (CR81) 2019; 30 Zappasodi (CR49) 2019; 25 Yu, Zheng, Mao, Su, Zhang (CR93) 2019; 10 Cohen (CR75) 2019; 7 Lucas, Negishi, Nakayama, Fields, Loh (CR84) 1995; 154 Allard, Allard, Buisseret, Stagg (CR138) 2020; 17 Effendi, Nagano, Kobayashi, Nishimura (CR139) 2020; 9 Krähenbühl (CR145) 2018; 20 Sukumar (CR50) 2017; 77 Li, Workman, Martin, Vignali (CR102) 2004; 173 Old (CR3) 1985; 230 Vence (CR47) 2019; 25 Wang (CR159) 2020; 26 Andtbacka (CR23) 2015; 33 Warner (CR57) 2018; 78 Curry (CR160) 2018; 8 Balmanoukian (CR52) 2020; 26 Segal (CR76) 2018; 24 Kang (CR113) 2015; 5 Ye (CR72) 2014; 20 Huang (CR114) 2015; 517 Manji (CR141) 2021; 39 Andrews, Marciscano, Drake, Vignali (CR89) 2017; 276 Leone, Emens (CR140) 2018; 6 Polesso, Sarker, Weinberg, Murray, Moran (CR62) 2019; 203 Shyer, Flavell, Bailis (CR38) 2020; 30 Kim (CR71) 2020; 71 Thoma (CR31) 2018; 15 Zhao, Zhao, Zhao (CR11) 2020; 12 Larkin (CR13) 2019; 381 O’Sullivan, Sanin, Pearce, Pearce (CR143) 2019; 19 Buchbinder, Desai (CR88) 2016; 39 Scharping (CR162) 2021; 22 CR25 Li (CR158) 2018; 78 Wang (CR55) 2018; 3 Watson (CR136) 2021; 591 Vardhana (CR137) 2020; 21 Gallimore, Hengartner, Zinkernagel (CR85) 1998; 164 O’Shaughnessy (CR30) 2018; 24 Gutierrez (CR67) 2021; 27 Toor, Sasidharan Nair, Decock, Elkord (CR128) 2020; 65 Zhao (CR43) 2011; 108 Wolchok (CR16) 2017; 377 C Thoma (552_CR31) 2018; 15 E Lozano (552_CR123) 2012; 188 M Gavrieli (552_CR127) 2003; 312 G Curigliano (552_CR117) 2019; 79 AS Balmanoukian (552_CR52) 2020; 26 S Spranger (552_CR21) 2018; 18 J Borst (552_CR34) 2018; 18 EJ Wherry (552_CR83) 2011; 12 GV Long (552_CR148) 2019; 20 Z Zou (552_CR155) 2020; 10 L Li (552_CR158) 2018; 78 EI Buchbinder (552_CR88) 2016; 39 PJ Martin (552_CR77) 1986; 136 F Triebel (552_CR95) 1990; 171 X Mao (552_CR100) 2016; 353 EEW Cohen (552_CR75) 2019; 7 NA Manieri (552_CR122) 2017; 38 E Reznik (552_CR133) 2018; 6 LP Andrews (552_CR89) 2017; 276 A Schietinger (552_CR86) 2014; 35 DN Khalil (552_CR22) 2019; 129 H Harjunpää (552_CR126) 2020; 200 L Wang (552_CR92) 2011; 208 YH Huang (552_CR114) 2015; 517 KA Frauwirth (552_CR131) 2002; 16 KM Heinhuis (552_CR53) 2020; 6 A Morales (552_CR4) 1976; 116 MR Middleton (552_CR24) 2020; 123 L Vence (552_CR47) 2019; 25 R Zappasodi (552_CR135) 2021; 591 XW Zhao (552_CR43) 2011; 108 PA Ascierto (552_CR109) 2017; 28 D O’Sullivan (552_CR143) 2019; 19 WI Effendi (552_CR139) 2020; 9 G Nocentini (552_CR45) 1997; 94 JA Marin-Acevedo (552_CR36) 2018; 11 P Prigent (552_CR106) 1999; 29 N Li (552_CR102) 2004; 173 M Krebs (552_CR108) 2020; 8 J Couzin-Frankel (552_CR6) 2013; 342 Q Zhang (552_CR119) 2018; 19 LJ Old (552_CR3) 1985; 230 S Sukumar (552_CR50) 2017; 77 D Rischin (552_CR81) 2019; 30 PA Mayes (552_CR40) 2018; 17 R Geva (552_CR54) 2018; 36 F Xu (552_CR99) 2014; 74 A Mullard (552_CR147) 2018; 17 JD Beck (552_CR44) 2021; 20 MZ Dewan (552_CR26) 2009; 15 MJ O’Shaughnessy (552_CR30) 2018; 24 JT Chang (552_CR151) 2007; 13 E Felip (552_CR146) 2020; 38 J Wang (552_CR101) 2019; 176 RD Leone (552_CR140) 2018; 6 N Koundouros (552_CR154) 2020; 122 B Wang (552_CR55) 2018; 3 Q Ye (552_CR72) 2014; 20 A Gallimore (552_CR85) 1998; 164 S Postel-Vinay (552_CR64) 2020; 80 JR Sedy (552_CR130) 2005; 6 R Zappasodi (552_CR49) 2019; 25 WL Hwang (552_CR28) 2018; 15 GJ Weiss (552_CR116) 2017; 5 MA Lakins (552_CR164) 2020; 26 M Saxena (552_CR32) 2021; 21 R Waitz (552_CR29) 2012; 72 TA Yap (552_CR80) 2018; 36 NM Chapman (552_CR37) 2020; 20 B Allard (552_CR138) 2020; 17 T Maruhashi (552_CR94) 2020; 8 DJ Messenheimer (552_CR70) 2017; 23 B Zhao (552_CR11) 2020; 12 DS Hong (552_CR110) 2018; 36 Y Wolf (552_CR118) 2020; 20 H Gmunder (552_CR78) 1984; 142 FS Hodi (552_CR8) 2010; 363 NH Segal (552_CR76) 2018; 24 SC Wei (552_CR82) 2017; 170 RK Vaddepally (552_CR9) 2020; 12 552_CR25 AM Gonzalez (552_CR51) 2017; 77 L Monney (552_CR90) 2002; 415 J Wolchok (552_CR7) 2018; 175 DE Speiser (552_CR87) 2014; 14 A Haslam (552_CR10) 2019; 2 GA Manji (552_CR141) 2021; 39 CT Huang (552_CR103) 2004; 21 JD Wolchok (552_CR16) 2017; 377 SA Vardhana (552_CR137) 2020; 21 S Wang (552_CR159) 2020; 26 J Larkin (552_CR13) 2019; 381 RCA Sainson (552_CR79) 2020; 8 J Galon (552_CR17) 2006; 313 NE Scharping (552_CR157) 2017; 5 F Liu (552_CR112) 2018; 11 SM Toor (552_CR128) 2020; 65 A Chiappori (552_CR68) 2020; 8 AM Gonzalez (552_CR60) 2017; 77 D Rodriguez-Abreu (552_CR124) 2020; 38 Y Jiang (552_CR129) 2015; 6 MJ Watson (552_CR136) 2021; 591 NE Scharping (552_CR162) 2021; 22 Y Jiang (552_CR42) 2021; 12 M Buzzai (552_CR156) 2007; 67 DA Knee (552_CR39) 2016; 67 DH Munn (552_CR142) 1999; 189 DO Khair (552_CR165) 2019; 10 S Guedan (552_CR73) 2018; 3 WB Coley (552_CR1) 1891; 14 C Brignone (552_CR107) 2009; 15 S Jeong (552_CR59) 2020; 20 AB El-Khoueiry (552_CR65) 2020; 38 CJ Workman (552_CR96) 2003; 33 M Gutierrez (552_CR67) 2021; 27 DA Schaer (552_CR61) 2013; 1 D Hirschhorn-Cymerman (552_CR63) 2009; 206 X Yu (552_CR93) 2019; 10 K Wang (552_CR150) 2013; 340 S-R Woo (552_CR105) 2012; 72 A Fuchs (552_CR120) 2006; 16 HW Chang (552_CR41) 2021; 118 AW Hahn (552_CR115) 2017; 9 PJ Lucas (552_CR84) 1995; 154 SA Rosenberg (552_CR5) 1994; 271 MA Postow (552_CR15) 2015; 372 E Baixeras (552_CR97) 1992; 176 R Geva (552_CR56) 2020; 126 D Schadendorf (552_CR12) 2015; 33 MA Postow (552_CR27) 2012; 366 D Bruni (552_CR18) 2020; 20 S Spranger (552_CR20) 2015; 523 NA Rizvi (552_CR19) 2015; 348 WJ Turbitt (552_CR163) 2020; 295 UH von Andrian (552_CR33) 2000; 343 M Das (552_CR111) 2017; 276 CW Kang (552_CR113) 2015; 5 B Tran (552_CR48) 2018; 6 F Polesso (552_CR62) 2019; 203 AB Warner (552_CR57) 2018; 78 S Sakaguchi (552_CR46) 1995; 155 X Yu (552_CR91) 2009; 10 MA Postow (552_CR14) 2018; 378 HD Kim (552_CR71) 2020; 71 J Zhao (552_CR58) 2010; 70 Z Liu (552_CR152) 2013; 44 JM Kirkwood (552_CR2) 2000; 18 X Qi (552_CR74) 2019; 10 JA Shyer (552_CR38) 2020; 30 L Krähenbühl (552_CR145) 2018; 20 I Svane (552_CR149) 2020; 31 JM Curry (552_CR160) 2018; 8 LP Andrews (552_CR104) 2020; 5 AM Kvarnhammar (552_CR69) 2019; 7 R Duhen (552_CR66) 2021; 12 MJ Ahn (552_CR125) 2020; 31 C Gutiérrez-Vázquez (552_CR144) 2018; 48 BC DiNatale (552_CR153) 2011; 50 A Teijeira (552_CR132) 2019; 7 RH Andtbacka (552_CR23) 2015; 33 S Tahara-Hanaoka (552_CR121) 2004; 16 C Coyle (552_CR161) 2016; 27 L Chen (552_CR35) 2013; 13 T Kouo (552_CR98) 2015; 3 CH Chang (552_CR134) 2016; 17 |
| References_xml | – volume: 21 start-page: 503 year: 2004 end-page: 513 ident: CR103 article-title: Role of LAG-3 in regulatory T cells publication-title: Immunity doi: 10.1016/j.immuni.2004.08.010 – volume: 415 start-page: 536 year: 2002 end-page: 541 ident: CR90 article-title: Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease publication-title: Nature doi: 10.1038/415536a – volume: 5 year: 2020 ident: CR104 article-title: Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abc2728 – volume: 378 start-page: 158 year: 2018 end-page: 168 ident: CR14 article-title: Immune-related adverse events associated with immune checkpoint blockade publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1703481 – volume: 27 start-page: 460 year: 2021 end-page: 472 ident: CR67 article-title: OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-1830 – volume: 20 start-page: 662 year: 2020 end-page: 680 ident: CR18 article-title: The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-020-0285-7 – volume: 39 start-page: 404 issue: Suppl. 3 year: 2021 ident: CR141 article-title: ARC-8: phase I/Ib study to evaluate safety and tolerability of AB680 + chemotherapy + zimberelimab (AB122) in patients with treatment-naive metastatic pancreatic adenocarcinoma (mPDAC) [abstract] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2021.39.3_suppl.404 – volume: 176 start-page: 327 year: 1992 end-page: 337 ident: CR97 article-title: Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens publication-title: J. Exp. Med. doi: 10.1084/jem.176.2.327 – volume: 122 start-page: 4 year: 2020 end-page: 22 ident: CR154 article-title: Reprogramming of fatty acid metabolism in cancer publication-title: Br. J. Cancer doi: 10.1038/s41416-019-0650-z – volume: 77 start-page: 4703 issue: Suppl. 13 year: 2017 ident: CR60 article-title: INCAGN1949, an anti-OX40 antibody with an optimal agonistic profile and the ability to selectively deplete intratumoral regulatory T cells [abstract] publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2017-4703 – volume: 30 start-page: v454 issue: Suppl. 5 year: 2019 end-page: v455 ident: CR81 article-title: Inducible T cell costimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and in combination with pembrolizumab (pembro): preliminary results from INDUCE-1 expansion cohorts (EC) in head and neck squamous cell carcinoma (HNSCC) [abstract 1119PD] publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz252.011 – volume: 8 start-page: 436 year: 2018 ident: CR160 article-title: Metformin clinical trial in HPV+ and HPV– head and neck squamous cell carcinoma: impact on cancer cell apoptosis and immune infiltrate publication-title: Front. Oncol. doi: 10.3389/fonc.2018.00436 – volume: 523 start-page: 231 year: 2015 end-page: 235 ident: CR20 article-title: Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity publication-title: Nature doi: 10.1038/nature14404 – volume: 348 start-page: 124 year: 2015 end-page: 128 ident: CR19 article-title: Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer publication-title: Science doi: 10.1126/science.aaa1348 – volume: 38 start-page: 3100 issue: Suppl. 15 year: 2020 ident: CR146 article-title: Initial results from a phase II study (TACTI-002) in metastatic non-small cell lung or head and neck carcinoma patients receiving eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab [abstract] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.15_suppl.3100 – volume: 20 start-page: 173 year: 2020 end-page: 185 ident: CR118 article-title: TIM3 comes of age as an inhibitory receptor publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0224-6 – volume: 13 start-page: 227 year: 2013 end-page: 242 ident: CR35 article-title: Molecular mechanisms of T cell co-stimulation and co-inhibition publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3405 – volume: 123 start-page: 885 year: 2020 end-page: 897 ident: CR24 article-title: Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives publication-title: Br. J. Cancer doi: 10.1038/s41416-020-0994-4 – volume: 18 start-page: 139 year: 2018 end-page: 147 ident: CR21 article-title: Impact of oncogenic pathways on evasion of antitumour immune responses publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.117 – ident: CR25 – volume: 155 start-page: 1151 year: 1995 end-page: 1164 ident: CR46 article-title: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases publication-title: J. Immunol. doi: 10.4049/jimmunol.155.3.1151 – volume: 15 start-page: 5379 year: 2009 end-page: 5388 ident: CR26 article-title: Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0265 – volume: 171 start-page: 1393 year: 1990 end-page: 1405 ident: CR95 article-title: LAG-3, a novel lymphocyte activation gene closely related to CD4 publication-title: J. Exp. Med. doi: 10.1084/jem.171.5.1393 – volume: 72 start-page: 917 year: 2012 end-page: 927 ident: CR105 article-title: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-1620 – volume: 170 start-page: 1120 year: 2017 end-page: 1133.e17 ident: CR82 article-title: Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade publication-title: Cell doi: 10.1016/j.cell.2017.07.024 – volume: 10 start-page: 31 year: 2020 ident: CR155 article-title: mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges publication-title: Cell Biosci. doi: 10.1186/s13578-020-00396-1 – volume: 8 year: 2020 ident: CR94 article-title: LAG-3: from molecular functions to clinical applications publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2020-001014 – volume: 342 start-page: 1432 year: 2013 end-page: 1433 ident: CR6 article-title: Cancer immunotherapy publication-title: Science doi: 10.1126/science.342.6165.1432 – volume: 77 start-page: 4378 year: 2017 end-page: 4388 ident: CR50 article-title: Characterization of MK-4166, a clinical agonistic antibody that targets human GITR and inhibits the generation and suppressive effects of T regulatory cells publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-1439 – volume: 3 year: 2018 ident: CR55 article-title: Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8(+) T cell dysfunction and maintain memory phenotype publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.aat7061 – volume: 8 start-page: A472 issue: Suppl. 3 year: 2020 end-page: A473 ident: CR108 article-title: A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC) [abstract 790] publication-title: J. Immunother. Cancer – volume: 1 start-page: 320 year: 2013 end-page: 331 ident: CR61 article-title: GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-13-0086 – volume: 12 year: 2021 ident: CR42 article-title: Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer publication-title: Nat. Commun. doi: 10.1038/s41467-021-21047-0 – volume: 19 start-page: 324 year: 2019 end-page: 335 ident: CR143 article-title: Metabolic interventions in the immune response to cancer publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0140-9 – volume: 35 start-page: 51 year: 2014 end-page: 60 ident: CR86 article-title: Tolerance and exhaustion: defining mechanisms of T cell dysfunction publication-title: Trends Immunol. doi: 10.1016/j.it.2013.10.001 – volume: 20 start-page: 1083 year: 2019 end-page: 1097 ident: CR148 article-title: Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30274-8 – volume: 271 start-page: 907 year: 1994 end-page: 913 ident: CR5 article-title: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 publication-title: JAMA doi: 10.1001/jama.1994.03510360033032 – volume: 12 start-page: 1758835920937612 year: 2020 ident: CR11 article-title: Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials publication-title: Ther. Adv. Med. Oncol. doi: 10.1177/1758835920937612 – volume: 80 start-page: CT150 issue: Suppl. 16 year: 2020 ident: CR64 article-title: A first-in-human phase I study of the OX40 agonist GSK3174998 (GSK998)+/- pembrolizumab in patients (Pts) with selected advanced solid tumors (ENGAGE-1) [abstract] publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2020-CT150 – volume: 312 start-page: 1236 year: 2003 end-page: 1243 ident: CR127 article-title: Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2003.11.070 – volume: 340 start-page: 63 year: 2013 end-page: 71 ident: CR150 article-title: An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells publication-title: Cancer Lett. doi: 10.1016/j.canlet.2013.06.026 – volume: 14 start-page: 768 year: 2014 end-page: 774 ident: CR87 article-title: T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion? publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3740 – volume: 70 start-page: 4850 year: 2010 end-page: 4858 ident: CR58 article-title: Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-0283 – volume: 276 start-page: 97 year: 2017 end-page: 111 ident: CR111 article-title: Tim-3 and its role in regulating anti-tumor immunity publication-title: Immunol. Rev. doi: 10.1111/imr.12520 – volume: 67 start-page: 1 year: 2016 end-page: 10 ident: CR39 article-title: Rationale for anti-GITR cancer immunotherapy publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2016.06.028 – volume: 33 start-page: 970 year: 2003 end-page: 979 ident: CR96 article-title: The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells publication-title: Eur. J. Immunol. doi: 10.1002/eji.200323382 – volume: 78 start-page: 1779 year: 2018 end-page: 1791 ident: CR158 article-title: Metformin-induced reduction of CD39 and CD73 blocks myeloid-derived suppressor cell activity in patients with ovarian cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-2460 – volume: 74 start-page: 3418 year: 2014 end-page: 3428 ident: CR99 article-title: LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-2690 – volume: 17 start-page: 611 year: 2020 end-page: 629 ident: CR138 article-title: The adenosine pathway in immuno-oncology publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0382-2 – volume: 25 start-page: 6501 year: 2019 end-page: 6510 ident: CR47 article-title: Characterization and comparison of GITR expression in solid tumors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-0289 – volume: 78 start-page: 1699 issue: Suppl. 13 year: 2018 ident: CR57 article-title: Treatment with agonist anti-GITR antibody after chemotherapy enhances tumor immunity [abstract] publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2018-1699 – volume: 21 start-page: 1022 year: 2020 end-page: 1033 ident: CR137 article-title: Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0725-2 – volume: 17 start-page: 307 year: 2018 ident: CR147 article-title: IDO takes a blow publication-title: Nat. Rev. Drug Discov. – volume: 313 start-page: 1960 year: 2006 end-page: 1964 ident: CR17 article-title: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome publication-title: Science doi: 10.1126/science.1129139 – volume: 48 start-page: 19 year: 2018 end-page: 33 ident: CR144 article-title: Regulation of the immune response by the aryl hydrocarbon receptor publication-title: Immunity doi: 10.1016/j.immuni.2017.12.012 – volume: 176 start-page: 334 year: 2019 end-page: 347 e312 ident: CR101 article-title: Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3 publication-title: Cell doi: 10.1016/j.cell.2018.11.010 – volume: 27 start-page: 2184 year: 2016 end-page: 2195 ident: CR161 article-title: Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw410 – volume: 44 start-page: 455 year: 2013 end-page: 461 ident: CR152 article-title: AhR expression is increased in hepatocellular carcinoma publication-title: J. Mol. Histol. doi: 10.1007/s10735-013-9495-6 – volume: 33 start-page: 2780 year: 2015 end-page: 2788 ident: CR23 article-title: Talimogene laherparepvec improves durable response rate in patients with advanced melanoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.58.3377 – volume: 118 year: 2021 ident: CR41 article-title: Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.2020606118 – volume: 12 start-page: 492 year: 2011 end-page: 499 ident: CR83 article-title: T cell exhaustion publication-title: Nat. Immunol. doi: 10.1038/ni.2035 – volume: 366 start-page: 925 year: 2012 end-page: 931 ident: CR27 article-title: Immunologic correlates of the abscopal effect in a patient with melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112824 – volume: 31 start-page: 1176 issue: Suppl. 4 year: 2020 ident: CR149 article-title: LBA48 clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial [abstract] publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.08.2278 – volume: 21 start-page: 360 year: 2021 end-page: 378 ident: CR32 article-title: Therapeutic cancer vaccines publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-021-00346-0 – volume: 343 start-page: 1020 year: 2000 end-page: 1034 ident: CR33 article-title: T-cell function and migration — two sides of the same coin publication-title: N. Engl. J. Med. doi: 10.1056/NEJM200010053431407 – volume: 12 start-page: 738 year: 2020 ident: CR9 article-title: Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence publication-title: Cancers (Basel) doi: 10.3390/cancers12030738 – volume: 36 start-page: 3029 issue: Suppl. 15 year: 2018 ident: CR54 article-title: First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors [abstract] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.3029 – volume: 20 start-page: 44 year: 2014 end-page: 55 ident: CR72 article-title: CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-0945 – volume: 38 start-page: 9503 issue: Suppl. 15 year: 2020 ident: CR124 article-title: Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE) [abstract] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.15_suppl.9503 – volume: 18 start-page: 2444 year: 2000 end-page: 2458 ident: CR2 article-title: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2000.18.12.2444 – volume: 6 year: 2015 ident: CR129 article-title: T-cell exhaustion in the tumor microenvironment publication-title: Cell Death Dis. doi: 10.1038/cddis.2015.162 – volume: 7 start-page: 342 year: 2019 ident: CR75 article-title: A phase Ib study of utomilumab (PF-05082566) in combination with mogamulizumab in patients with advanced solid tumors publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0815-6 – volume: 142 start-page: 153 year: 1984 end-page: 160 ident: CR78 article-title: A 45-kDa human T-cell membrane glycoprotein functions in the regulation of cell proliferative responses publication-title: Eur. J. Biochem. doi: 10.1111/j.1432-1033.1984.tb08263.x – volume: 77 start-page: 3643 issue: Suppl. 13 year: 2017 ident: CR51 article-title: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization [abstract] publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2017-3643 – volume: 71 start-page: 955 year: 2020 end-page: 971 ident: CR71 article-title: 4-1BB delineates distinct activation status of exhausted tumor-infiltrating CD8(+) T cells in hepatocellular carcinoma publication-title: Hepatology doi: 10.1002/hep.30881 – volume: 6 start-page: 301 year: 2018 end-page: 313.e3 ident: CR133 article-title: A landscape of metabolic variation across tumor types publication-title: Cell Syst. doi: 10.1016/j.cels.2017.12.014 – volume: 116 start-page: 180 year: 1976 end-page: 183 ident: CR4 article-title: Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors publication-title: J. Urol. doi: 10.1016/S0022-5347(17)58737-6 – volume: 12 year: 2021 ident: CR66 article-title: Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells publication-title: Nat. Commun. doi: 10.1038/s41467-021-21383-1 – volume: 33 start-page: 1889 year: 2015 end-page: 1894 ident: CR12 article-title: Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.56.2736 – volume: 381 start-page: 1535 year: 2019 end-page: 1546 ident: CR13 article-title: Five-year survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1910836 – volume: 8 start-page: 1568 year: 2020 end-page: 1582 ident: CR79 article-title: An antibody targeting ICOS increases intratumoral cytotoxic to regulatory T-cell ratio and induces tumor regression publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-20-0034 – volume: 10 start-page: 453 year: 2019 ident: CR165 article-title: Combining immune checkpoint inhibitors: established and emerging targets and strategies to improve outcomes in Melanoma publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.00453 – volume: 39 start-page: 98 year: 2016 end-page: 106 ident: CR88 article-title: CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition publication-title: Am. J. Clin. Oncol. doi: 10.1097/COC.0000000000000239 – volume: 10 start-page: 48 year: 2009 end-page: 57 ident: CR91 article-title: The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells publication-title: Nat. Immunol. doi: 10.1038/ni.1674 – volume: 50 start-page: 173 year: 2011 end-page: 183 ident: CR153 article-title: Ah receptor antagonism inhibits constitutive and cytokine inducible IL6 production in head and neck tumor cell lines publication-title: Mol. Carcinog. doi: 10.1002/mc.20702 – volume: 10 start-page: 617 year: 2019 ident: CR93 article-title: BTLA/HVEM signaling: milestones in research and role in chronic hepatitis B virus infection publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.00617 – volume: 13 start-page: 38 year: 2007 end-page: 45 ident: CR151 article-title: Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-1166 – volume: 38 start-page: 20 year: 2017 end-page: 28 ident: CR122 article-title: TIGIT: a key inhibitor of the cancer immunity cycle publication-title: Trends Immunol. doi: 10.1016/j.it.2016.10.002 – volume: 5 year: 2015 ident: CR113 article-title: Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer publication-title: Sci. Rep. doi: 10.1038/srep15659 – volume: 7 start-page: 103 year: 2019 ident: CR69 article-title: The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0570-8 – volume: 36 start-page: 3000 issue: Suppl. 15 year: 2018 ident: CR80 article-title: ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers [abstract] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.3000 – volume: 353 start-page: aah3374 year: 2016 ident: CR100 article-title: Pathological α-synuclein transmission initiated by binding lymphocyte-activation gene 3 publication-title: Science doi: 10.1126/science.aah3374 – volume: 108 start-page: 18342 year: 2011 end-page: 18347 ident: CR43 article-title: CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1106550108 – volume: 200 start-page: 108 year: 2020 end-page: 119 ident: CR126 article-title: TIGIT as an emerging immune checkpoint publication-title: Clin. Exp. Immunol. doi: 10.1111/cei.13407 – volume: 230 start-page: 630 year: 1985 end-page: 632 ident: CR3 article-title: Tumor necrosis factor (TNF) publication-title: Science doi: 10.1126/science.2413547 – volume: 14 start-page: 199 year: 1891 end-page: 220 ident: CR1 article-title: II. Contribution to the knowledge of sarcoma publication-title: Ann. Surg. doi: 10.1097/00000658-189112000-00015 – volume: 203 start-page: 2011 year: 2019 end-page: 2019 ident: CR62 article-title: OX40 agonist tumor immunotherapy does not impact regulatory T cell suppressive function publication-title: J. Immunol. doi: 10.4049/jimmunol.1900696 – volume: 6 start-page: 90 year: 2005 end-page: 98 ident: CR130 article-title: B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator publication-title: Nat. Immunol. doi: 10.1038/ni1144 – volume: 372 start-page: 2006 year: 2015 end-page: 2017 ident: CR15 article-title: Nivolumab and ipilimumab versus ipilimumab in untreated melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1414428 – volume: 28 start-page: 611 issue: Suppl. 5 year: 2017 end-page: 612 ident: CR109 article-title: Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy (mel prior IO) in all-comer and biomarker-enriched populations [abstract LBA18] publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx440.011 – volume: 17 start-page: 509 year: 2018 end-page: 527 ident: CR40 article-title: The promise and challenges of immune agonist antibody development in cancer publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.75 – volume: 208 start-page: 577 year: 2011 end-page: 592 ident: CR92 article-title: VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses publication-title: J. Exp. Med. doi: 10.1084/jem.20100619 – volume: 26 start-page: 4154 year: 2020 end-page: 4167 ident: CR164 article-title: FS222, a CD137/PD-L1 tetravalent bispecific antibody, exhibits low toxicity and antitumor activity in colorectal cancer models publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-2958 – volume: 11 start-page: 126 year: 2018 ident: CR112 article-title: Tim-3 expression and its role in hepatocellular carcinoma publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-018-0667-4 – volume: 6 start-page: 100 year: 2020 end-page: 107 ident: CR53 article-title: Safety, tolerability, and potential clinical activity of a glucocorticoid-induced TNF receptor–related protein agonist alone or in combination with nivolumab for patients with advanced solid tumors: a phase 1/2a dose-escalation and cohort-expansion clinical trial publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.3848 – volume: 9 start-page: 681 year: 2017 end-page: 692 ident: CR115 article-title: The future of immune checkpoint cancer therapy after PD-1 and CTLA-4 publication-title: Immunotherapy doi: 10.2217/imt-2017-0024 – volume: 591 start-page: 645 year: 2021 end-page: 651 ident: CR136 article-title: Metabolic support of tumour-infiltrating regulatory T cells by lactic acid publication-title: Nature doi: 10.1038/s41586-020-03045-2 – volume: 67 start-page: 6745 year: 2007 end-page: 6752 ident: CR156 article-title: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-4447 – volume: 175 start-page: 1452 year: 2018 end-page: 1454 ident: CR7 article-title: Putting the immunologic brakes on cancer publication-title: Cell doi: 10.1016/j.cell.2018.11.006 – volume: 25 start-page: 759 year: 2019 end-page: 766 ident: CR49 article-title: Rational design of anti-GITR-based combination immunotherapy publication-title: Nat. Med. doi: 10.1038/s41591-019-0420-8 – volume: 20 start-page: 218 year: 2018 end-page: 225 ident: CR145 article-title: A longitudinal analysis of IDO and PDL1 expression during immune- or targeted therapy in advanced melanoma publication-title: Neoplasia doi: 10.1016/j.neo.2017.12.002 – volume: 188 start-page: 3869 year: 2012 end-page: 3875 ident: CR123 article-title: The TIGIT/CD226 axis regulates human T cell function publication-title: J. Immunol. doi: 10.4049/jimmunol.1103627 – volume: 9 start-page: 785 year: 2020 ident: CR139 article-title: Focusing on adenosine receptors as a potential targeted therapy in human diseases publication-title: Cells doi: 10.3390/cells9030785 – volume: 6 start-page: 57 year: 2018 ident: CR140 article-title: Targeting adenosine for cancer immunotherapy publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0360-8 – volume: 295 start-page: 203 year: 2020 end-page: 219 ident: CR163 article-title: Obesity and CD8 T cell metabolism: implications for anti-tumor immunity and cancer immunotherapy outcomes publication-title: Immunol. Rev. doi: 10.1111/imr.12849 – volume: 591 start-page: 652 year: 2021 end-page: 658 ident: CR135 article-title: CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours publication-title: Nature doi: 10.1038/s41586-021-03326-4 – volume: 363 start-page: 711 year: 2010 end-page: 723 ident: CR8 article-title: Improved survival with ipilimumab in patients with metastatic melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 15 start-page: 6225 year: 2009 end-page: 6231 ident: CR107 article-title: A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0068 – volume: 6 start-page: 93 year: 2018 ident: CR48 article-title: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0407-x – volume: 173 start-page: 6806 year: 2004 end-page: 6812 ident: CR102 article-title: Biochemical analysis of the regulatory T cell protein lymphocyte activation gene-3 (LAG-3; CD223) publication-title: J. Immunol. doi: 10.4049/jimmunol.173.11.6806 – volume: 517 start-page: 386 year: 2015 end-page: 390 ident: CR114 article-title: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion publication-title: Nature doi: 10.1038/nature13848 – volume: 15 start-page: 477 year: 2018 end-page: 494 ident: CR28 article-title: Safety of combining radiotherapy with immune-checkpoint inhibition publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-018-0046-7 – volume: 11 start-page: 39 year: 2018 ident: CR36 article-title: Next generation of immune checkpoint therapy in cancer: new developments and challenges publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-018-0582-8 – volume: 30 start-page: 649 year: 2020 end-page: 659 ident: CR38 article-title: Metabolic signaling in T cells publication-title: Cell Res. doi: 10.1038/s41422-020-0379-5 – volume: 206 start-page: 1103 year: 2009 end-page: 1116 ident: CR63 article-title: OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis publication-title: J. Exp. Med. doi: 10.1084/jem.20082205 – volume: 276 start-page: 80 year: 2017 end-page: 96 ident: CR89 article-title: LAG3 (CD223) as a cancer immunotherapy target publication-title: Immunol. Rev. doi: 10.1111/imr.12519 – volume: 129 start-page: 3435 year: 2019 end-page: 3447 ident: CR22 article-title: In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors publication-title: J. Clin. Invest. doi: 10.1172/JCI128562 – volume: 65 start-page: 1 year: 2020 end-page: 12 ident: CR128 article-title: Immune checkpoints in the tumor microenvironment publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.06.021 – volume: 126 start-page: 4926 year: 2020 end-page: 4935 ident: CR56 article-title: First-in-human phase 1 study of MK-1248, an anti–glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors publication-title: Cancer doi: 10.1002/cncr.33133 – volume: 17 start-page: 364 year: 2016 end-page: 368 ident: CR134 article-title: Emerging concepts of T cell metabolism as a target of immunotherapy publication-title: Nat. Immunol. doi: 10.1038/ni.3415 – volume: 10 year: 2019 ident: CR74 article-title: Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity publication-title: Nat. Commun. doi: 10.1038/s41467-019-10088-1 – volume: 29 start-page: 3867 year: 1999 end-page: 3876 ident: CR106 article-title: Lymphocyte activation gene-3 induces tumor regression and antitumor immune responses publication-title: Eur. J. Immunol. doi: 10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E – volume: 377 start-page: 1345 year: 2017 end-page: 1356 ident: CR16 article-title: Overall survival with combined nivolumab and ipilimumab in advanced melanoma publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1709684 – volume: 5 start-page: 9 year: 2017 end-page: 16 ident: CR157 article-title: Efficacy of PD-1 blockade is potentiated by metformin-induced reduction of tumor hypoxia publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0103 – volume: 38 start-page: 523 issue: Suppl. 4 year: 2020 ident: CR65 article-title: Analysis of OX40 agonist antibody (PF-04518600) in patients with hepatocellular carcinoma [abstract] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.4_suppl.523 – volume: 15 start-page: 204 year: 2018 ident: CR31 article-title: Enhancing VTP publication-title: Nat. Rev. Urol. doi: 10.1038/nrurol.2018.32 – volume: 164 start-page: 29 year: 1998 end-page: 36 ident: CR85 article-title: Hierarchies of antigen-specific cytotoxic T-cell responses publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.1998.tb01205.x – volume: 136 start-page: 3282 year: 1986 end-page: 3287 ident: CR77 article-title: A 44 kilodalton cell surface homodimer regulates interleukin 2 production by activated human T lymphocytes publication-title: J. Immunol. doi: 10.4049/jimmunol.136.9.3282 – volume: 16 start-page: 533 year: 2004 end-page: 538 ident: CR121 article-title: Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112) publication-title: Int. Immunol. doi: 10.1093/intimm/dxh059 – volume: 18 start-page: 635 year: 2018 end-page: 647 ident: CR34 article-title: CD4+ T cell help in cancer immunology and immunotherapy publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-018-0044-0 – volume: 19 start-page: 723 year: 2018 end-page: 732 ident: CR119 article-title: Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity publication-title: Nat. Immunol. doi: 10.1038/s41590-018-0132-0 – volume: 5 start-page: O13 issue: Suppl. 2 year: 2017 ident: CR116 article-title: A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors [abstract] publication-title: J. Immunother. Cancer – volume: 8 start-page: A9 issue: Suppl. 1 year: 2020 end-page: A10 ident: CR68 article-title: Results from a combination of OX40 (PF-04518600) and 4–1BB (utomilumab) agonistic antibodies in melanoma and non-small cell lung cancer in a phase 1 dose expansion cohort [abstract P860] publication-title: J. Immunother. Cancer – volume: 31 start-page: S887 issue: Suppl. 4 year: 2020 ident: CR125 article-title: Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC [abstract 1400P] publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.08.1714 – volume: 3 start-page: 412 year: 2015 end-page: 423 ident: CR98 article-title: Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-14-0150 – volume: 154 start-page: 5757 year: 1995 end-page: 5768 ident: CR84 article-title: Naive CD28-deficient T cells can initiate but not sustain an in vitro antigen-specific immune response publication-title: J. Immunol. doi: 10.4049/jimmunol.154.11.5757 – volume: 20 year: 2021 ident: CR44 article-title: mRNA therapeutics in cancer immunotherapy publication-title: Mol. Cancer doi: 10.1186/s12943-021-01348-0 – volume: 189 start-page: 1363 year: 1999 end-page: 1372 ident: CR142 article-title: Inhibition of T cell proliferation by macrophage tryptophan catabolism publication-title: J. Exp. Med. doi: 10.1084/jem.189.9.1363 – volume: 94 start-page: 6216 year: 1997 end-page: 6221 ident: CR45 article-title: A new member of the tumor necrosis factor/nerve growth factor receptor family inhibits T cell receptor-induced apoptosis publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.94.12.6216 – volume: 20 year: 2020 ident: CR59 article-title: Co-stimulatory receptors in cancers and their implications for cancer immunotherapy publication-title: Immune Netw. doi: 10.4110/in.2020.20.e3 – volume: 36 start-page: 3012 issue: Suppl. 15 year: 2018 ident: CR110 article-title: Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies [abstract] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.3012 – volume: 79 start-page: CT183 issue: Suppl. 13 year: 2019 ident: CR117 article-title: Phase (Ph) I/II study of MBG453± spartalizumab (PDR001) in patients (pts) with advanced malignancies [abstract] publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2019-CT183 – volume: 2 year: 2019 ident: CR10 article-title: Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.2535 – volume: 72 start-page: 430 year: 2012 end-page: 439 ident: CR29 article-title: Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-1782 – volume: 16 start-page: 769 year: 2002 end-page: 777 ident: CR131 article-title: The CD28 signaling pathway regulates glucose metabolism publication-title: Immunity doi: 10.1016/S1074-7613(02)00323-0 – volume: 20 start-page: 55 year: 2020 end-page: 70 ident: CR37 article-title: Metabolic coordination of T cell quiescence and activation publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0203-y – volume: 26 start-page: 6196 year: 2020 end-page: 6203 ident: CR52 article-title: Safety and clinical activity of MEDI1873, a novel GITR agonist, in advanced solid tumors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-0452 – volume: 16 start-page: 359 year: 2006 end-page: 366 ident: CR120 article-title: The role of NK cell recognition of nectin and nectin-like proteins in tumor immunosurveillance publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2006.07.002 – volume: 7 start-page: 1564 year: 2019 end-page: 1569 ident: CR132 article-title: Metabolic consequences of T-cell costimulation in anticancer immunity publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-19-0115 – volume: 26 start-page: 4921 year: 2020 end-page: 4932 ident: CR159 article-title: Low-dose metformin reprograms the tumor immune microenvironment in human esophageal cancer: results of a phase II clinical trial publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-0113 – volume: 24 start-page: 1816 year: 2018 end-page: 1823 ident: CR76 article-title: Phase I study of single-agent Utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in oatients with advanced cancer publication-title: Cin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-1922 – volume: 22 start-page: 205 year: 2021 end-page: 215 ident: CR162 article-title: Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion publication-title: Nat. Immunol. doi: 10.1038/s41590-020-00834-9 – volume: 24 start-page: 592 year: 2018 end-page: 599 ident: CR30 article-title: Systemic antitumor immunity by PD-1/PD-L1 inhibition is potentiated by vascular-targeted photodynamic therapy of primary tumors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-0186 – volume: 23 start-page: 6165 year: 2017 end-page: 6177 ident: CR70 article-title: Timing of PD-1 blockade is critical to effective combination immunotherapy with anti-OX40 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2677 – volume: 3 year: 2018 ident: CR73 article-title: Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation publication-title: JCI Insight doi: 10.1172/jci.insight.96976 – volume: 27 start-page: 2184 year: 2016 ident: 552_CR161 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdw410 – volume: 72 start-page: 917 year: 2012 ident: 552_CR105 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-1620 – volume: 20 start-page: 55 year: 2020 ident: 552_CR37 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0203-y – ident: 552_CR25 – volume: 19 start-page: 324 year: 2019 ident: 552_CR143 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0140-9 – volume: 6 start-page: 100 year: 2020 ident: 552_CR53 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2019.3848 – volume: 10 year: 2019 ident: 552_CR74 publication-title: Nat. Commun. doi: 10.1038/s41467-019-10088-1 – volume: 48 start-page: 19 year: 2018 ident: 552_CR144 publication-title: Immunity doi: 10.1016/j.immuni.2017.12.012 – volume: 3 year: 2018 ident: 552_CR73 publication-title: JCI Insight doi: 10.1172/jci.insight.96976 – volume: 14 start-page: 199 year: 1891 ident: 552_CR1 publication-title: Ann. Surg. doi: 10.1097/00000658-189112000-00015 – volume: 206 start-page: 1103 year: 2009 ident: 552_CR63 publication-title: J. Exp. Med. doi: 10.1084/jem.20082205 – volume: 17 start-page: 611 year: 2020 ident: 552_CR138 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-0382-2 – volume: 26 start-page: 4921 year: 2020 ident: 552_CR159 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-0113 – volume: 170 start-page: 1120 year: 2017 ident: 552_CR82 publication-title: Cell doi: 10.1016/j.cell.2017.07.024 – volume: 20 start-page: 44 year: 2014 ident: 552_CR72 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-0945 – volume: 5 year: 2015 ident: 552_CR113 publication-title: Sci. Rep. doi: 10.1038/srep15659 – volume: 13 start-page: 227 year: 2013 ident: 552_CR35 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3405 – volume: 70 start-page: 4850 year: 2010 ident: 552_CR58 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-0283 – volume: 20 start-page: 173 year: 2020 ident: 552_CR118 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-019-0224-6 – volume: 33 start-page: 970 year: 2003 ident: 552_CR96 publication-title: Eur. J. Immunol. doi: 10.1002/eji.200323382 – volume: 20 year: 2021 ident: 552_CR44 publication-title: Mol. Cancer doi: 10.1186/s12943-021-01348-0 – volume: 7 start-page: 342 year: 2019 ident: 552_CR75 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0815-6 – volume: 9 start-page: 681 year: 2017 ident: 552_CR115 publication-title: Immunotherapy doi: 10.2217/imt-2017-0024 – volume: 5 start-page: O13 issue: Suppl. 2 year: 2017 ident: 552_CR116 publication-title: J. Immunother. Cancer – volume: 340 start-page: 63 year: 2013 ident: 552_CR150 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2013.06.026 – volume: 7 start-page: 103 year: 2019 ident: 552_CR69 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-019-0570-8 – volume: 30 start-page: 649 year: 2020 ident: 552_CR38 publication-title: Cell Res. doi: 10.1038/s41422-020-0379-5 – volume: 36 start-page: 3029 issue: Suppl. 15 year: 2018 ident: 552_CR54 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.3029 – volume: 372 start-page: 2006 year: 2015 ident: 552_CR15 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1414428 – volume: 14 start-page: 768 year: 2014 ident: 552_CR87 publication-title: Nat. Rev. Immunol. doi: 10.1038/nri3740 – volume: 38 start-page: 9503 issue: Suppl. 15 year: 2020 ident: 552_CR124 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.15_suppl.9503 – volume: 142 start-page: 153 year: 1984 ident: 552_CR78 publication-title: Eur. J. Biochem. doi: 10.1111/j.1432-1033.1984.tb08263.x – volume: 18 start-page: 139 year: 2018 ident: 552_CR21 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc.2017.117 – volume: 77 start-page: 4703 issue: Suppl. 13 year: 2017 ident: 552_CR60 publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2017-4703 – volume: 19 start-page: 723 year: 2018 ident: 552_CR119 publication-title: Nat. Immunol. doi: 10.1038/s41590-018-0132-0 – volume: 381 start-page: 1535 year: 2019 ident: 552_CR13 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1910836 – volume: 175 start-page: 1452 year: 2018 ident: 552_CR7 publication-title: Cell doi: 10.1016/j.cell.2018.11.006 – volume: 26 start-page: 6196 year: 2020 ident: 552_CR52 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-0452 – volume: 36 start-page: 3012 issue: Suppl. 15 year: 2018 ident: 552_CR110 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.3012 – volume: 8 start-page: A9 issue: Suppl. 1 year: 2020 ident: 552_CR68 publication-title: J. Immunother. Cancer – volume: 10 start-page: 617 year: 2019 ident: 552_CR93 publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.00617 – volume: 80 start-page: CT150 issue: Suppl. 16 year: 2020 ident: 552_CR64 publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2020-CT150 – volume: 154 start-page: 5757 year: 1995 ident: 552_CR84 publication-title: J. Immunol. doi: 10.4049/jimmunol.154.11.5757 – volume: 30 start-page: v454 issue: Suppl. 5 year: 2019 ident: 552_CR81 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdz252.011 – volume: 276 start-page: 97 year: 2017 ident: 552_CR111 publication-title: Immunol. Rev. doi: 10.1111/imr.12520 – volume: 203 start-page: 2011 year: 2019 ident: 552_CR62 publication-title: J. Immunol. doi: 10.4049/jimmunol.1900696 – volume: 136 start-page: 3282 year: 1986 ident: 552_CR77 publication-title: J. Immunol. doi: 10.4049/jimmunol.136.9.3282 – volume: 8 start-page: 1568 year: 2020 ident: 552_CR79 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-20-0034 – volume: 363 start-page: 711 year: 2010 ident: 552_CR8 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1003466 – volume: 13 start-page: 38 year: 2007 ident: 552_CR151 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-1166 – volume: 17 start-page: 307 year: 2018 ident: 552_CR147 publication-title: Nat. Rev. Drug Discov. – volume: 5 start-page: 9 year: 2017 ident: 552_CR157 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-16-0103 – volume: 200 start-page: 108 year: 2020 ident: 552_CR126 publication-title: Clin. Exp. Immunol. doi: 10.1111/cei.13407 – volume: 72 start-page: 430 year: 2012 ident: 552_CR29 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-11-1782 – volume: 38 start-page: 20 year: 2017 ident: 552_CR122 publication-title: Trends Immunol. doi: 10.1016/j.it.2016.10.002 – volume: 67 start-page: 6745 year: 2007 ident: 552_CR156 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-4447 – volume: 29 start-page: 3867 year: 1999 ident: 552_CR106 publication-title: Eur. J. Immunol. doi: 10.1002/(SICI)1521-4141(199912)29:12<3867::AID-IMMU3867>3.0.CO;2-E – volume: 10 start-page: 31 year: 2020 ident: 552_CR155 publication-title: Cell Biosci. doi: 10.1186/s13578-020-00396-1 – volume: 9 start-page: 785 year: 2020 ident: 552_CR139 publication-title: Cells doi: 10.3390/cells9030785 – volume: 6 start-page: 93 year: 2018 ident: 552_CR48 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0407-x – volume: 6 start-page: 57 year: 2018 ident: 552_CR140 publication-title: J. Immunother. Cancer doi: 10.1186/s40425-018-0360-8 – volume: 39 start-page: 404 issue: Suppl. 3 year: 2021 ident: 552_CR141 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2021.39.3_suppl.404 – volume: 108 start-page: 18342 year: 2011 ident: 552_CR43 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1106550108 – volume: 171 start-page: 1393 year: 1990 ident: 552_CR95 publication-title: J. Exp. Med. doi: 10.1084/jem.171.5.1393 – volume: 123 start-page: 885 year: 2020 ident: 552_CR24 publication-title: Br. J. Cancer doi: 10.1038/s41416-020-0994-4 – volume: 78 start-page: 1699 issue: Suppl. 13 year: 2018 ident: 552_CR57 publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2018-1699 – volume: 176 start-page: 327 year: 1992 ident: 552_CR97 publication-title: J. Exp. Med. doi: 10.1084/jem.176.2.327 – volume: 94 start-page: 6216 year: 1997 ident: 552_CR45 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.94.12.6216 – volume: 65 start-page: 1 year: 2020 ident: 552_CR128 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2019.06.021 – volume: 17 start-page: 364 year: 2016 ident: 552_CR134 publication-title: Nat. Immunol. doi: 10.1038/ni.3415 – volume: 377 start-page: 1345 year: 2017 ident: 552_CR16 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1709684 – volume: 312 start-page: 1236 year: 2003 ident: 552_CR127 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2003.11.070 – volume: 21 start-page: 360 year: 2021 ident: 552_CR32 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-021-00346-0 – volume: 27 start-page: 460 year: 2021 ident: 552_CR67 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-20-1830 – volume: 116 start-page: 180 year: 1976 ident: 552_CR4 publication-title: J. Urol. doi: 10.1016/S0022-5347(17)58737-6 – volume: 353 start-page: aah3374 year: 2016 ident: 552_CR100 publication-title: Science doi: 10.1126/science.aah3374 – volume: 35 start-page: 51 year: 2014 ident: 552_CR86 publication-title: Trends Immunol. doi: 10.1016/j.it.2013.10.001 – volume: 378 start-page: 158 year: 2018 ident: 552_CR14 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMra1703481 – volume: 230 start-page: 630 year: 1985 ident: 552_CR3 publication-title: Science doi: 10.1126/science.2413547 – volume: 591 start-page: 652 year: 2021 ident: 552_CR135 publication-title: Nature doi: 10.1038/s41586-021-03326-4 – volume: 18 start-page: 2444 year: 2000 ident: 552_CR2 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2000.18.12.2444 – volume: 44 start-page: 455 year: 2013 ident: 552_CR152 publication-title: J. Mol. Histol. doi: 10.1007/s10735-013-9495-6 – volume: 15 start-page: 5379 year: 2009 ident: 552_CR26 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0265 – volume: 415 start-page: 536 year: 2002 ident: 552_CR90 publication-title: Nature doi: 10.1038/415536a – volume: 16 start-page: 533 year: 2004 ident: 552_CR121 publication-title: Int. Immunol. doi: 10.1093/intimm/dxh059 – volume: 348 start-page: 124 year: 2015 ident: 552_CR19 publication-title: Science doi: 10.1126/science.aaa1348 – volume: 8 year: 2020 ident: 552_CR94 publication-title: J. Immunother. Cancer doi: 10.1136/jitc-2020-001014 – volume: 189 start-page: 1363 year: 1999 ident: 552_CR142 publication-title: J. Exp. Med. doi: 10.1084/jem.189.9.1363 – volume: 3 year: 2018 ident: 552_CR55 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.aat7061 – volume: 313 start-page: 1960 year: 2006 ident: 552_CR17 publication-title: Science doi: 10.1126/science.1129139 – volume: 71 start-page: 955 year: 2020 ident: 552_CR71 publication-title: Hepatology doi: 10.1002/hep.30881 – volume: 129 start-page: 3435 year: 2019 ident: 552_CR22 publication-title: J. Clin. Invest. doi: 10.1172/JCI128562 – volume: 77 start-page: 4378 year: 2017 ident: 552_CR50 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-1439 – volume: 126 start-page: 4926 year: 2020 ident: 552_CR56 publication-title: Cancer doi: 10.1002/cncr.33133 – volume: 38 start-page: 3100 issue: Suppl. 15 year: 2020 ident: 552_CR146 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.15_suppl.3100 – volume: 31 start-page: S887 issue: Suppl. 4 year: 2020 ident: 552_CR125 publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.08.1714 – volume: 10 start-page: 453 year: 2019 ident: 552_CR165 publication-title: Front. Immunol. doi: 10.3389/fimmu.2019.00453 – volume: 6 start-page: 301 year: 2018 ident: 552_CR133 publication-title: Cell Syst. doi: 10.1016/j.cels.2017.12.014 – volume: 31 start-page: 1176 issue: Suppl. 4 year: 2020 ident: 552_CR149 publication-title: Ann. Oncol. doi: 10.1016/j.annonc.2020.08.2278 – volume: 12 year: 2021 ident: 552_CR66 publication-title: Nat. Commun. doi: 10.1038/s41467-021-21383-1 – volume: 155 start-page: 1151 year: 1995 ident: 552_CR46 publication-title: J. Immunol. doi: 10.4049/jimmunol.155.3.1151 – volume: 164 start-page: 29 year: 1998 ident: 552_CR85 publication-title: Immunol. Rev. doi: 10.1111/j.1600-065X.1998.tb01205.x – volume: 21 start-page: 503 year: 2004 ident: 552_CR103 publication-title: Immunity doi: 10.1016/j.immuni.2004.08.010 – volume: 24 start-page: 1816 year: 2018 ident: 552_CR76 publication-title: Cin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-1922 – volume: 8 start-page: 436 year: 2018 ident: 552_CR160 publication-title: Front. Oncol. doi: 10.3389/fonc.2018.00436 – volume: 33 start-page: 2780 year: 2015 ident: 552_CR23 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.58.3377 – volume: 15 start-page: 477 year: 2018 ident: 552_CR28 publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-018-0046-7 – volume: 33 start-page: 1889 year: 2015 ident: 552_CR12 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.56.2736 – volume: 118 year: 2021 ident: 552_CR41 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.2020606118 – volume: 276 start-page: 80 year: 2017 ident: 552_CR89 publication-title: Immunol. Rev. doi: 10.1111/imr.12519 – volume: 11 start-page: 126 year: 2018 ident: 552_CR112 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-018-0667-4 – volume: 12 start-page: 175883592093761 year: 2020 ident: 552_CR11 publication-title: Ther. Adv. Med. Oncol. doi: 10.1177/1758835920937612 – volume: 3 start-page: 412 year: 2015 ident: 552_CR98 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-14-0150 – volume: 343 start-page: 1020 year: 2000 ident: 552_CR33 publication-title: N. Engl. J. Med. doi: 10.1056/NEJM200010053431407 – volume: 208 start-page: 577 year: 2011 ident: 552_CR92 publication-title: J. Exp. Med. doi: 10.1084/jem.20100619 – volume: 1 start-page: 320 year: 2013 ident: 552_CR61 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-13-0086 – volume: 271 start-page: 907 year: 1994 ident: 552_CR5 publication-title: JAMA doi: 10.1001/jama.1994.03510360033032 – volume: 67 start-page: 1 year: 2016 ident: 552_CR39 publication-title: Eur. J. Cancer doi: 10.1016/j.ejca.2016.06.028 – volume: 7 start-page: 1564 year: 2019 ident: 552_CR132 publication-title: Cancer Immunol. Res. doi: 10.1158/2326-6066.CIR-19-0115 – volume: 25 start-page: 759 year: 2019 ident: 552_CR49 publication-title: Nat. Med. doi: 10.1038/s41591-019-0420-8 – volume: 173 start-page: 6806 year: 2004 ident: 552_CR102 publication-title: J. Immunol. doi: 10.4049/jimmunol.173.11.6806 – volume: 18 start-page: 635 year: 2018 ident: 552_CR34 publication-title: Nat. Rev. Immunol. doi: 10.1038/s41577-018-0044-0 – volume: 20 start-page: 1083 year: 2019 ident: 552_CR148 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(19)30274-8 – volume: 79 start-page: CT183 issue: Suppl. 13 year: 2019 ident: 552_CR117 publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2019-CT183 – volume: 78 start-page: 1779 year: 2018 ident: 552_CR158 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-2460 – volume: 16 start-page: 769 year: 2002 ident: 552_CR131 publication-title: Immunity doi: 10.1016/S1074-7613(02)00323-0 – volume: 295 start-page: 203 year: 2020 ident: 552_CR163 publication-title: Immunol. Rev. doi: 10.1111/imr.12849 – volume: 188 start-page: 3869 year: 2012 ident: 552_CR123 publication-title: J. Immunol. doi: 10.4049/jimmunol.1103627 – volume: 74 start-page: 3418 year: 2014 ident: 552_CR99 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-13-2690 – volume: 36 start-page: 3000 issue: Suppl. 15 year: 2018 ident: 552_CR80 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2018.36.15_suppl.3000 – volume: 25 start-page: 6501 year: 2019 ident: 552_CR47 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-0289 – volume: 28 start-page: 611 issue: Suppl. 5 year: 2017 ident: 552_CR109 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdx440.011 – volume: 22 start-page: 205 year: 2021 ident: 552_CR162 publication-title: Nat. Immunol. doi: 10.1038/s41590-020-00834-9 – volume: 176 start-page: 334 year: 2019 ident: 552_CR101 publication-title: Cell doi: 10.1016/j.cell.2018.11.010 – volume: 21 start-page: 1022 year: 2020 ident: 552_CR137 publication-title: Nat. Immunol. doi: 10.1038/s41590-020-0725-2 – volume: 12 year: 2021 ident: 552_CR42 publication-title: Nat. Commun. doi: 10.1038/s41467-021-21047-0 – volume: 342 start-page: 1432 year: 2013 ident: 552_CR6 publication-title: Science doi: 10.1126/science.342.6165.1432 – volume: 10 start-page: 48 year: 2009 ident: 552_CR91 publication-title: Nat. Immunol. doi: 10.1038/ni.1674 – volume: 39 start-page: 98 year: 2016 ident: 552_CR88 publication-title: Am. J. Clin. Oncol. doi: 10.1097/COC.0000000000000239 – volume: 8 start-page: A472 issue: Suppl. 3 year: 2020 ident: 552_CR108 publication-title: J. Immunother. Cancer – volume: 12 start-page: 492 year: 2011 ident: 552_CR83 publication-title: Nat. Immunol. doi: 10.1038/ni.2035 – volume: 20 year: 2020 ident: 552_CR59 publication-title: Immune Netw. doi: 10.4110/in.2020.20.e3 – volume: 6 start-page: 90 year: 2005 ident: 552_CR130 publication-title: Nat. Immunol. doi: 10.1038/ni1144 – volume: 38 start-page: 523 issue: Suppl. 4 year: 2020 ident: 552_CR65 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2020.38.4_suppl.523 – volume: 23 start-page: 6165 year: 2017 ident: 552_CR70 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2677 – volume: 15 start-page: 204 year: 2018 ident: 552_CR31 publication-title: Nat. Rev. Urol. doi: 10.1038/nrurol.2018.32 – volume: 523 start-page: 231 year: 2015 ident: 552_CR20 publication-title: Nature doi: 10.1038/nature14404 – volume: 20 start-page: 662 year: 2020 ident: 552_CR18 publication-title: Nat. Rev. Cancer doi: 10.1038/s41568-020-0285-7 – volume: 11 start-page: 39 year: 2018 ident: 552_CR36 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-018-0582-8 – volume: 26 start-page: 4154 year: 2020 ident: 552_CR164 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-19-2958 – volume: 517 start-page: 386 year: 2015 ident: 552_CR114 publication-title: Nature doi: 10.1038/nature13848 – volume: 16 start-page: 359 year: 2006 ident: 552_CR120 publication-title: Semin. Cancer Biol. doi: 10.1016/j.semcancer.2006.07.002 – volume: 6 year: 2015 ident: 552_CR129 publication-title: Cell Death Dis. doi: 10.1038/cddis.2015.162 – volume: 15 start-page: 6225 year: 2009 ident: 552_CR107 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-0068 – volume: 20 start-page: 218 year: 2018 ident: 552_CR145 publication-title: Neoplasia doi: 10.1016/j.neo.2017.12.002 – volume: 2 year: 2019 ident: 552_CR10 publication-title: JAMA Netw. Open doi: 10.1001/jamanetworkopen.2019.2535 – volume: 24 start-page: 592 year: 2018 ident: 552_CR30 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-17-0186 – volume: 50 start-page: 173 year: 2011 ident: 552_CR153 publication-title: Mol. Carcinog. doi: 10.1002/mc.20702 – volume: 122 start-page: 4 year: 2020 ident: 552_CR154 publication-title: Br. J. Cancer doi: 10.1038/s41416-019-0650-z – volume: 17 start-page: 509 year: 2018 ident: 552_CR40 publication-title: Nat. Rev. Drug Discov. doi: 10.1038/nrd.2018.75 – volume: 12 start-page: 738 year: 2020 ident: 552_CR9 publication-title: Cancers (Basel) doi: 10.3390/cancers12030738 – volume: 77 start-page: 3643 issue: Suppl. 13 year: 2017 ident: 552_CR51 publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2017-3643 – volume: 591 start-page: 645 year: 2021 ident: 552_CR136 publication-title: Nature doi: 10.1038/s41586-020-03045-2 – volume: 5 year: 2020 ident: 552_CR104 publication-title: Sci. Immunol. doi: 10.1126/sciimmunol.abc2728 – volume: 366 start-page: 925 year: 2012 ident: 552_CR27 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1112824 |
| SSID | ssj0066473 |
| Score | 2.727804 |
| SecondaryResourceType | review_article |
| Snippet | The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as... |
| SourceID | proquest pubmed crossref springer |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 37 |
| SubjectTerms | 631/67/580 692/4028/67/1059/2325 692/699/67/1059/153 692/699/67/2327 692/699/67/327 Adenosine BTLA protein Cancer Clinical trials CTLA-4 protein Glucose metabolism Humans Immune checkpoint Immune checkpoint inhibitors Immune Checkpoint Inhibitors - pharmacology Immune Checkpoint Inhibitors - therapeutic use Immunologic Factors - metabolism Immunomodulation Immunomodulators Immunotherapy Immunotherapy - methods Lymphocytes Lymphocytes T Medicine Medicine & Public Health Metabolism Neoplasms - therapy Oncology Patients PD-1 protein PD-L1 protein Receptor mechanisms Review Article Signal transduction T cell receptors Tumor necrosis factor Tumors |
| Title | Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways |
| URI | https://link.springer.com/article/10.1038/s41571-021-00552-7 https://www.ncbi.nlm.nih.gov/pubmed/34580473 https://www.proquest.com/docview/2611009616 https://www.proquest.com/docview/2577454074 |
| Volume | 19 |
| WOSCitedRecordID | wos000701025500003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1759-4782 dateEnd: 20241212 omitProxy: false ssIdentifier: ssj0066473 issn: 1759-4774 databaseCode: 7RV dateStart: 20090401 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dT9swED9tME28wL6AMFZl0t62CCdxYucJDVS0l1Ud2qa-RbGdlEqQQFNA_e-5c5xWCI2XPcRSlItj5c7273xfAF8M02GhmCYLowq4inSAtyLQsipQA4lUGRlbbEKMRnIyycbuwK11bpX9mmgXatNoOiM_QqQf2vok6fH1TUBVo8i66kpovITNkLAxyrM4_9uvxGnKrYUZd8gs4IhzXNAMi-VRixuXQEU6woslCaLMxxvTE7T5xFJqN6Cznf8d-hvYdtDT_97Jylt4Udbv4PVPZ1x_D7-G9QVl36in_oyiRlxs1tKf1b4m4Zj7aul3ruNERKHF0zX1VWOoFFgzX_pU5vi-WLYf4M_Z8Pfpj8BVXAg0wqJFkFYmKUUlS66zmBlV8SJKjNFChanJEqE1YyqtqgqBIuqKUhRSUjSU0YZ0Rx3vwkbd1OU-uUylwmQqFnGU8VBzmRopkCopZWEKVnkQ9r871y4dOVXFuMytWTyWeceiHDvOLYty4cHX1TvXXTKOZ6kPe3bkbmK2-ZoXHnxePcYpRXaSoi6bW6RJUFYoMSH3YK_j_upzMU8kQ7Hy4FsvDuvO_z2Wg-fH8hG2IgqrsEc7h7CxmN-Wn-CVvlvM2vnACjW1E2FbOYDNk-FofD4gT9XxAxG6ADc |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3Nb5VAEJ_UatSL3x9oVUz0pKQLLOxyMMZomzZtXzSpybtt2Q_qSxTq49WGf8q_0ZkF3otp7K0HDxwIw7IwP-ZjZ2cG4JVlJi41MxRh1BHXiYnwVERGViV6IIl2ifXNJsRkIqfT4vMa_B5zYWhb5SgTvaC2jaE18k209GPfnyR_f_Izoq5RFF0dW2j0sNhz3Rm6bO273U_I39dJsr11-HEnGroKRAZV_yLKK5s5UUnHTZEyqyteJpm1Rug4t0UmjGFM51VVoTGE_pAUpZSU8WONJf_IpDjuFbiKclyQsyemSwcvz7mPaKNGLiKOdtWQpMNSudmiohTouCd4sCxDq_ZvRXjOuj0XmfUKb_v2__ap7sCtwbQOP_T_wl1Yc_U9uH4wbB64D1-26m9UXaQ-DmeUFTPknnXhrA4NgX8e6i7st8YTEaVOH6-ofzSWWp018y6kNs5nZdc-gK-X8kIPYb1uaveYtoTlwhY6FWlS8NhwmVspkCpzsrQlqwKIR_YqM5Rbp64f35UP-6dS9ZBQOLDykFAigDfLe076YiMXUm-M7FeD4GnVivcBvFxeRpFBcaCyds0p0mSITSq8yAN41KNt-biUZ5IhjAN4O8JvNfi_5_Lk4rm8gBs7hwf7an93svcUbiaUQuKXsTZgfTE_dc_gmvm1mLXz5_6HCuHosmH5B1RCWVg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9NAFH4qKaq4sC-GAkaCE1ixx2PP-IAQ0ERUhSggkHobPItLJLBLnFL5r_HreM9LIlTRWw8cfLD8PB7b37xl3gbw1IYmynVoyMOoA66ZCfBUBEYWOVogTDtm22YTYjaTh4fZfAt-D7kwFFY58MSWUdvK0B75GDX9qO1Pko6LPixivjd9dfwzoA5S5Gkd2ml0EDlwzSmab_XL_T38188Ym04-v30X9B0GAoNqwCpIC5s4UUjHTRaHVhc8Z4m1RugotVkijAlDnRZFgYoR2kZS5FJS9o81lmwlE-O4l2BboJLBR7D9ZjKbfxrkQJry1r-N8jkLOGpZfcpOGMtxjWJToBnP8AiTBHXcv8XiGV33jJ-2FX_Ta__zh7sOV3ul23_drZIbsOXKm7DzoQ8ruAUfJ-U3qjtSHvkLypfps9Iaf1H6hpbF0teN3wXNExElVR9tqH9UlpqgVcvGpwbPp3lT34YvF_JCd2BUVqW7R8FiqbCZjkXMMh4ZLlMrBVIlTuY2DwsPouFXK9MXYqd-IN9VGxAQS9XBQ-HAqoWHEh48X99z3JUhOZd6d4CC6llSrTY48ODJ-jIyE_IQ5aWrTpAmQZxSSUbuwd0OeevHxTyRIULagxcDFDeD_3su98-fy2PYQTSq9_uzgwdwhVFuSbu_tQuj1fLEPYTL5tdqUS8f9avLh68Xjcs_WE9jeA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhancing+immunotherapy+in+cancer+by+targeting+emerging+immunomodulatory+pathways&rft.jtitle=Nature+reviews.+Clinical+oncology&rft.au=Kraehenbuehl%2C+Lukas&rft.au=Weng%2C+Chien-Huan&rft.au=Eghbali%2C+Shabnam&rft.au=Wolchok%2C+Jedd+D&rft.date=2022-01-01&rft.issn=1759-4782&rft.eissn=1759-4782&rft.volume=19&rft.issue=1&rft.spage=37&rft_id=info:doi/10.1038%2Fs41571-021-00552-7&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1759-4774&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1759-4774&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1759-4774&client=summon |